UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. |
As previously disclosed, on March 11, 2021, Colfax Corporation (the “Company”) is holding an Investor Day beginning at 9:00 a.m. Eastern time. In connection with this event, the Company will provide additional information with respect to the Company’s previously announced intention to separate its fabrication technology and specialty medical technology businesses into two differentiated, independent and publicly traded companies, as well as a detailed discussion of each business. A copy of the Investor Day presentation is furnished herewith as Exhibit 99.1.
A live webcast of the event can be accessed beginning at 9:00 a.m. Eastern time through the Company’s website at
www.colfaxcorp.com under the “Investors” section. The Investor Day presentation and replays of the webcast will be available on the Company’s website under the “Investors” section following the event.
The information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 | Investor Day presentation, dated March 11, 2021. | |
| 104 | Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 11, 2021
| COLFAX CORPORATION | ||
| By: | /s/ Christopher M. Hix | |
| Name: | Christopher M. Hix | |
| Title: | Executive Vice President, Finance | |
| Chief Financial Officer (Principal Financial Officer) | ||
Exhibit 99.1 Colfax Corporation Investor Day March 11, 2021 Exhibit 99.1 Colfax Corporation Investor Day March 11, 2021
Forward Looking Statement & Non-GAAP Disclaimer These materials include “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by terms such as “believe,” “anticipate,” “should,” “would,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “targets,” “aims,” “seeks,” “sees” and similar expressions. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to, statements regarding: the intended separation of the FabTech and MedTech businesses; expected 2021 revenue and Adjusted EBITDA for FabTech and MedTech; long-term financial goals for FabTech and MedTech; the timing and method of the separation; the anticipated benefits of the separation; the expected financial and operating performance of, and future opportunities for, each company following the separation; the tax treatment of the transaction; and the leadership of each company following the separation. These statements are based on assumptions and assessments made by our management as of the date of this presentation in light of their experience and perception of historical trends, current conditions, expected future developments, strategy, outlook, goals and other factors believed to be appropriate. Forward-looking statements are subject to a number of risks, uncertainties and assumptions that might cause actual results, developments and business decisions to differ materially from those expressed or implied thereby, and are not guarantees of future performance or actual results. These factors include, among other things: the final approval of the separation by our board of directors; the uncertainty of obtaining regulatory approvals in connection with the separation, including rulings from the Internal Revenue Service; the ability to successfully complete financing and other transactions on satisfactory terms, and other steps necessary to qualify the separation as a tax-free transaction; the ability to satisfy the necessary closing conditions to complete the separation on a timely basis, or at all; our ability to successfully separate the two companies and realize the anticipated benefits of the separation; developments related to the impact of the COVID-19 pandemic on the separation and the financial and operating performance of each company following the separation, including actions by governments, businesses and individuals in response to the pandemic, and other impacts on our business and ability to execute business continuity plans; and our ability to manage and grow our business and to execute our business and growth strategies. The effects of the COVID-19 pandemic, including actions by governments, businesses and individuals in response to the pandemic, may also give rise or contribute to or amplify the risks associated with many of these factors. The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Other unknown or unpredictable factors could also cause actual results, developments and business decisions to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements should be construed in the light of such factors. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Additional information regarding these and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements is set forth in our public filings with the Securities Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2020 and our subsequent filings with the SEC. We do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise. Colfax has provided in this presentation certain financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures include adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITDA margin, organic (core) sales growth, and free cash flow. Colfax also provides adjusted EBITDA, adjusted EBITDA margin, organic (core) sales growth and free cash flow on a segment basis. • Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash charges, European Union Medical Device Regulation (“MDR”) and other costs, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income. • Adjusted EBITDA represents Adjusted EBITA plus depreciation and other amortization. • Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. • Decremental margin represents the change in Adjusted EBITDA divided by the change in net sales. • Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment. These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation. In this presentation, Colfax presents forward-looking non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITA and Free Cash Flow on a segment basis. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate such measures can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis. 2Forward Looking Statement & Non-GAAP Disclaimer These materials include “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by terms such as “believe,” “anticipate,” “should,” “would,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “targets,” “aims,” “seeks,” “sees” and similar expressions. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to, statements regarding: the intended separation of the FabTech and MedTech businesses; expected 2021 revenue and Adjusted EBITDA for FabTech and MedTech; long-term financial goals for FabTech and MedTech; the timing and method of the separation; the anticipated benefits of the separation; the expected financial and operating performance of, and future opportunities for, each company following the separation; the tax treatment of the transaction; and the leadership of each company following the separation. These statements are based on assumptions and assessments made by our management as of the date of this presentation in light of their experience and perception of historical trends, current conditions, expected future developments, strategy, outlook, goals and other factors believed to be appropriate. Forward-looking statements are subject to a number of risks, uncertainties and assumptions that might cause actual results, developments and business decisions to differ materially from those expressed or implied thereby, and are not guarantees of future performance or actual results. These factors include, among other things: the final approval of the separation by our board of directors; the uncertainty of obtaining regulatory approvals in connection with the separation, including rulings from the Internal Revenue Service; the ability to successfully complete financing and other transactions on satisfactory terms, and other steps necessary to qualify the separation as a tax-free transaction; the ability to satisfy the necessary closing conditions to complete the separation on a timely basis, or at all; our ability to successfully separate the two companies and realize the anticipated benefits of the separation; developments related to the impact of the COVID-19 pandemic on the separation and the financial and operating performance of each company following the separation, including actions by governments, businesses and individuals in response to the pandemic, and other impacts on our business and ability to execute business continuity plans; and our ability to manage and grow our business and to execute our business and growth strategies. The effects of the COVID-19 pandemic, including actions by governments, businesses and individuals in response to the pandemic, may also give rise or contribute to or amplify the risks associated with many of these factors. The factors identified above are not exhaustive. We operate in a dynamic business environment in which new risks may emerge frequently. Other unknown or unpredictable factors could also cause actual results, developments and business decisions to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements should be construed in the light of such factors. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made. Additional information regarding these and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements is set forth in our public filings with the Securities Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2020 and our subsequent filings with the SEC. We do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise. Colfax has provided in this presentation certain financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures include adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITDA margin, organic (core) sales growth, and free cash flow. Colfax also provides adjusted EBITDA, adjusted EBITDA margin, organic (core) sales growth and free cash flow on a segment basis. • Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, acquisition-related amortization and other non-cash charges, European Union Medical Device Regulation (“MDR”) and other costs, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, where we exclude the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income. • Adjusted EBITDA represents Adjusted EBITA plus depreciation and other amortization. • Core or organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. • Decremental margin represents the change in Adjusted EBITDA divided by the change in net sales. • Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment. These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of Colfax. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that Colfax uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures provided in the appendix to this presentation. In this presentation, Colfax presents forward-looking non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITA and Free Cash Flow on a segment basis. Colfax does not provide such outlook on a GAAP basis because changes in the items that Colfax excludes from GAAP to calculate such measures can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Colfax’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis. 2
Agenda Q&A Logistics Mitch Rales 9:00 AM Chairman’s Introduction • Ask questions by clicking submit Matt Trerotola Colfax Capabilities, Strategic Direction 9:20 AM question, next to presenter box within the meeting 9:40 AM Q&A 10:00 AM Shyam Kambeyanda ESAB Strategy, Progress, Opportunities Olivier Biebuyck Kevin Johnson 10:45 AM Q&A 11:00 AM Break MedTechCo Strategy, Progress, Matt Trerotola 11:15 AM Opportunities Brady Shirley Louie Vogt Steve Ingel • Once submitted, questions will Ben Berry remain in the queue 12:15 PM Q&A 12:30 PM Colfax Financial Update & Wrap-Up Chris Hix 12:45 PM Q&A 3Agenda Q&A Logistics Mitch Rales 9:00 AM Chairman’s Introduction • Ask questions by clicking submit Matt Trerotola Colfax Capabilities, Strategic Direction 9:20 AM question, next to presenter box within the meeting 9:40 AM Q&A 10:00 AM Shyam Kambeyanda ESAB Strategy, Progress, Opportunities Olivier Biebuyck Kevin Johnson 10:45 AM Q&A 11:00 AM Break MedTechCo Strategy, Progress, Matt Trerotola 11:15 AM Opportunities Brady Shirley Louie Vogt Steve Ingel • Once submitted, questions will Ben Berry remain in the queue 12:15 PM Q&A 12:30 PM Colfax Financial Update & Wrap-Up Chris Hix 12:45 PM Q&A 3
Chairman’s Introduction – Mitch Rales 4Chairman’s Introduction – Mitch Rales 4
Separation Overview th Announced on March 4 the intent to separate into two independent, publicly traded companies (completion targeted in the first quarter 2022) Creates focused specialty Medical Technologies and Fabrication Technology companies, positioning both to accelerate strategic momentum Enables each company to sharpen its strategic focus to capitalize on distinct investment opportunities Allows each to be valued based on distinct strategic, operational and financial characteristics Now is the right time to build on the momentum in both businesses 5Separation Overview th Announced on March 4 the intent to separate into two independent, publicly traded companies (completion targeted in the first quarter 2022) Creates focused specialty Medical Technologies and Fabrication Technology companies, positioning both to accelerate strategic momentum Enables each company to sharpen its strategic focus to capitalize on distinct investment opportunities Allows each to be valued based on distinct strategic, operational and financial characteristics Now is the right time to build on the momentum in both businesses 5
Re-Shaped Portfolio for Maximum Value Creation 2017-2019 Transformation 2019-2020 Momentum 2021 - Future • Portfolio changes • Strengthened talent, accelerated • Leaders in attractive, growing MedTech capabilities markets • Created outperforming FabTech business • Invested in innovation and • Sustainable business models for strategic acquisitions compounding value creation 1 $3.5B sales $3B+ Specialty MedTechCo with FabTech MedTech HSD Growth, Capital Allocation (ESAB) (DJO) Focused on Growth $3B+ FabTech Leader with MSD FabTech Divested Growth, Balanced Capital Businesses (ESAB) Allocation 2017 2019 Businesses are Ready to be Independent, Publicly-Traded Companies 6 1 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019Re-Shaped Portfolio for Maximum Value Creation 2017-2019 Transformation 2019-2020 Momentum 2021 - Future • Portfolio changes • Strengthened talent, accelerated • Leaders in attractive, growing MedTech capabilities markets • Created outperforming FabTech business • Invested in innovation and • Sustainable business models for strategic acquisitions compounding value creation 1 $3.5B sales $3B+ Specialty MedTechCo with FabTech MedTech HSD Growth, Capital Allocation (ESAB) (DJO) Focused on Growth $3B+ FabTech Leader with MSD FabTech Divested Growth, Balanced Capital Businesses (ESAB) Allocation 2017 2019 Businesses are Ready to be Independent, Publicly-Traded Companies 6 1 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019
Two Great Companies, Well-Positioned for Success Global Fabrication Technology Leader Specialty Medical Technology Innovator MedTechCo • >$30B market, global GDP + accelerators • >$50B market, healthcare growth drivers • Global leader with scale in all regions • Focused in attractive segments • Strong brands and innovation engine • Strong brands, innovation building • Automating industrial workflows • Automating clinic workflows Key Peers MedTech MidCaps Ortho Leaders FabTech Leaders Ossur Stryker Lincoln Electric Conmed Zimmer Biomet ITW - Miller Teleflex Wright Medical* Large, Attractive Markets Great Opportunities for Profitable Growth 7 * Recently acquired by StrykerTwo Great Companies, Well-Positioned for Success Global Fabrication Technology Leader Specialty Medical Technology Innovator MedTechCo • >$30B market, global GDP + accelerators • >$50B market, healthcare growth drivers • Global leader with scale in all regions • Focused in attractive segments • Strong brands and innovation engine • Strong brands, innovation building • Automating industrial workflows • Automating clinic workflows Key Peers MedTech MidCaps Ortho Leaders FabTech Leaders Ossur Stryker Lincoln Electric Conmed Zimmer Biomet ITW - Miller Teleflex Wright Medical* Large, Attractive Markets Great Opportunities for Profitable Growth 7 * Recently acquired by Stryker
Colfax Sustainable Model for Compounding Value Creation Talent Above-Market Sales Growth CBS / Continuous Improvement Compounding Margin Expansion Value Creation Innovation Healthy Free Cash Flow Acquisitions / Portfolio Shaping Each Business now has these Core Capabilities to Drive Superior Performance 8Colfax Sustainable Model for Compounding Value Creation Talent Above-Market Sales Growth CBS / Continuous Improvement Compounding Margin Expansion Value Creation Innovation Healthy Free Cash Flow Acquisitions / Portfolio Shaping Each Business now has these Core Capabilities to Drive Superior Performance 8
Strong Cultures and Talent Processes Our Talent Imperatives Our Culture Outstanding Talent 1 CBS-capable GMs and ops leaders; business-minded functional leads Full Bench 2 Depth & breadth for growth including acquisition integration Right Organization 3 Aligned for optimal performance & appropriately incentivized Engaged, Diverse, Inclusive 4 Motivated, developed, challenged, and supported Culture and Talent are Critical to Executing our Strategy to Compound Value 9Strong Cultures and Talent Processes Our Talent Imperatives Our Culture Outstanding Talent 1 CBS-capable GMs and ops leaders; business-minded functional leads Full Bench 2 Depth & breadth for growth including acquisition integration Right Organization 3 Aligned for optimal performance & appropriately incentivized Engaged, Diverse, Inclusive 4 Motivated, developed, challenged, and supported Culture and Talent are Critical to Executing our Strategy to Compound Value 9
Strong Leadership Teams in Place to Drive Superior Performance ESAB MedTechCo Shyam Kambeyanda Matt Trerotola Brady Shirley President & CEO CEO President & COO Kevin Scott Michele Curtis Chris Hix Dan Pryor Patty Lang Brad Tandy CFO Strategy/BD GC CHRO Johnson Grisham Campion Jewell CFO Strategy/BD CHRO GC Seasoned Leaders with Deep Bench 10Strong Leadership Teams in Place to Drive Superior Performance ESAB MedTechCo Shyam Kambeyanda Matt Trerotola Brady Shirley President & CEO CEO President & COO Kevin Scott Michele Curtis Chris Hix Dan Pryor Patty Lang Brad Tandy CFO Strategy/BD GC CHRO Johnson Grisham Campion Jewell CFO Strategy/BD CHRO GC Seasoned Leaders with Deep Bench 10
Colfax Business System (CBS) Drives Continuous Improvement • Culture + Processes + Tools • Builds momentum over time • ESAB far into CBS journey, accelerating performance • DJO businesses now have CBS foundation, momentum building Both Companies Will Carry forward CBS Culture, Tools, and Processes 11Colfax Business System (CBS) Drives Continuous Improvement • Culture + Processes + Tools • Builds momentum over time • ESAB far into CBS journey, accelerating performance • DJO businesses now have CBS foundation, momentum building Both Companies Will Carry forward CBS Culture, Tools, and Processes 11
Demonstrated Innovation Engines Growing Digital Initiatives in Both Businesses • ESAB’s industry-leading innovation contributing to organic growth, share gain, higher margins • MedTechCo Reconstructive vitality high, supporting double-digit growth • MedTechCo Prevention & Recovery leading in clinic workflow, pipeline full, vitality increasing MedTechCo’s Accelerating Innovation ESAB’s Best-in-Class Innovation Program Product Introductions (#) Product Introductions (#) +230% +300% 2020 Vitality Index 2020 Vitality Index 80 32 Prevention & Recovery 3-year >17% ▪ 3-year >11% ▪ Reconstructive 24 8 5-year >30% ▪ 3-year >30+% ▪ 2020 2016 2020 2017 Accelerating Innovation Pace Creates Additional Growth Opportunities 12Demonstrated Innovation Engines Growing Digital Initiatives in Both Businesses • ESAB’s industry-leading innovation contributing to organic growth, share gain, higher margins • MedTechCo Reconstructive vitality high, supporting double-digit growth • MedTechCo Prevention & Recovery leading in clinic workflow, pipeline full, vitality increasing MedTechCo’s Accelerating Innovation ESAB’s Best-in-Class Innovation Program Product Introductions (#) Product Introductions (#) +230% +300% 2020 Vitality Index 2020 Vitality Index 80 32 Prevention & Recovery 3-year >17% ▪ 3-year >11% ▪ Reconstructive 24 8 5-year >30% ▪ 3-year >30+% ▪ 2020 2016 2020 2017 Accelerating Innovation Pace Creates Additional Growth Opportunities 12
Disciplined, Strategy-Driven Acquisition Process ESAB MedTechCo Channel/Global Specialty Alloys Robotics & Recovery Science Modalities Automation Solutions Surgical Workflow Digital Growth Foot/Ankle Medical & Specialty STAR Expansion Total ankle replacement Gas Control 7 acquisitions over past 5 years adding 6 acquisitions over the past year expanding technology, diversifying markets markets, improving growth rate and margins Capabilities firmly established in both businesses Acquisition Process Creates Faster, More Predictable Growth & Higher Margins 13Disciplined, Strategy-Driven Acquisition Process ESAB MedTechCo Channel/Global Specialty Alloys Robotics & Recovery Science Modalities Automation Solutions Surgical Workflow Digital Growth Foot/Ankle Medical & Specialty STAR Expansion Total ankle replacement Gas Control 7 acquisitions over past 5 years adding 6 acquisitions over the past year expanding technology, diversifying markets markets, improving growth rate and margins Capabilities firmly established in both businesses Acquisition Process Creates Faster, More Predictable Growth & Higher Margins 13
Colfax Model Drove Significant Improvement and Evolution ESAB, past 5 years MedTechCo, past 2 years Seasoned team, deep bench, CBS Retained and strengthened team, CBS Talent embedded in DNA journey well underway • Strong service, consistent productivity • Insourced distribution Supply Chains • Consolidations for regional scale • Improved service, productivity building • >3X increase in launches • Improved and funded, >3X launches Innovation • Consistent high vitality • Sustained strong surgical vitality Engines • MotionMD™ from ~1000 to >2000 clinics • Industry-leading WeldCloud™ Workflow/ • First 2 connected brace launches • Robotics solutions Software • Surgical workflow technology investments • Accelerated growth, improved gross • Improved margins, growth Portfolio margins • Accessed attractive $3B specialty gas • Accessed high growth $1B foot/ankle mkt control Powerful Impact, Capabilities Embedded 14Colfax Model Drove Significant Improvement and Evolution ESAB, past 5 years MedTechCo, past 2 years Seasoned team, deep bench, CBS Retained and strengthened team, CBS Talent embedded in DNA journey well underway • Strong service, consistent productivity • Insourced distribution Supply Chains • Consolidations for regional scale • Improved service, productivity building • >3X increase in launches • Improved and funded, >3X launches Innovation • Consistent high vitality • Sustained strong surgical vitality Engines • MotionMD™ from ~1000 to >2000 clinics • Industry-leading WeldCloud™ Workflow/ • First 2 connected brace launches • Robotics solutions Software • Surgical workflow technology investments • Accelerated growth, improved gross • Improved margins, growth Portfolio margins • Accessed attractive $3B specialty gas • Accessed high growth $1B foot/ankle mkt control Powerful Impact, Capabilities Embedded 14
Executing Our Strategy Compounds Value Great service + high vitality + commercial excellence leads to organic growth above market Margin expansion and cash conversion improvement driven by CBS, Great Markets, Strong Positions and Momentum supports ability to make strategic investments Successful acquisitions improve growth & gross margins over time provides more cash to invest Both Businesses have Strong Paths for Compounding Value Creation 15Executing Our Strategy Compounds Value Great service + high vitality + commercial excellence leads to organic growth above market Margin expansion and cash conversion improvement driven by CBS, Great Markets, Strong Positions and Momentum supports ability to make strategic investments Successful acquisitions improve growth & gross margins over time provides more cash to invest Both Businesses have Strong Paths for Compounding Value Creation 15
Realizing Our Vision ESAB Aspiration: MedTechCo Aspiration: MSD Core Growth HSD Core Growth 1 1 aEBITDA Margin >20% Mid-60’s GM%/aEBITDA Margin >25% 100%+ cash flow conversion, balanced allocation Strong cash flow, invest for growth Extend into attractive adjacencies ~$2.5B ~$1.7-$2B Accelerators ~$2.2B ~$1.4B Aggressively Scale Recon grow & expand Recon Continue to lead in FabTech Extend P&R Improve and leadership shape P&R 2021E ~2023 Future 2021E ~2023 Future P&R Recon New 16 1 Segment-level margin Realizing Our Vision ESAB Aspiration: MedTechCo Aspiration: MSD Core Growth HSD Core Growth 1 1 aEBITDA Margin >20% Mid-60’s GM%/aEBITDA Margin >25% 100%+ cash flow conversion, balanced allocation Strong cash flow, invest for growth Extend into attractive adjacencies ~$2.5B ~$1.7-$2B Accelerators ~$2.2B ~$1.4B Aggressively Scale Recon grow & expand Recon Continue to lead in FabTech Extend P&R Improve and leadership shape P&R 2021E ~2023 Future 2021E ~2023 Future P&R Recon New 16 1 Segment-level margin
Summary ✓ Taking the next logical step, given transformation of both businesses and opportunities ahead ✓ Strong momentum in both businesses ✓ Exciting visions for ESAB and MedTechCo ✓ Separation should enable both businesses to achieve visions and unlock value 17Summary ✓ Taking the next logical step, given transformation of both businesses and opportunities ahead ✓ Strong momentum in both businesses ✓ Exciting visions for ESAB and MedTechCo ✓ Separation should enable both businesses to achieve visions and unlock value 17
Q&AQ&A
ESAB: Global Leader in Fabrication Technology INVESTOR DAY PRESENTATION MARCH 11, 2021ESAB: Global Leader in Fabrication Technology INVESTOR DAY PRESENTATION MARCH 11, 2021
Best Team Wins: ESAB Presenters Shyam Kambeyanda Olivier Biebuyck Kevin Johnson Chief Executive Officer President EMEA, Equipment, and Digital Chief Financial Officer ▪▪▪ Solutions Joined ESAB in 2016 Joined ESAB in 2019 ▪▪ Joined ESAB in 2017 ▪ Previously worked at Eaton Corporation Experienced Colfax financial executive, ▪▪ Previously worked at Honeywell, joined company in 2001 ▪ LafargeHolcim, and McKinsey & Company 20 ESAB – A Fabrication Technology LeaderBest Team Wins: ESAB Presenters Shyam Kambeyanda Olivier Biebuyck Kevin Johnson Chief Executive Officer President EMEA, Equipment, and Digital Chief Financial Officer ▪▪▪ Solutions Joined ESAB in 2016 Joined ESAB in 2019 ▪▪ Joined ESAB in 2017 ▪ Previously worked at Eaton Corporation Experienced Colfax financial executive, ▪▪ Previously worked at Honeywell, joined company in 2001 ▪ LafargeHolcim, and McKinsey & Company 20 ESAB – A Fabrication Technology Leader
A Premier Global Fabrication Technology Company Organic Continuous Long-Term Growth Improvement Acquisitions Talent Strategic Goal Innovation Colfax Business Higher growth, higher Core values ▪▪▪▪ $3B+ System (CBS) gross margin, and lower Global Presence Attract and retain best cyclicality Revenue ▪▪ Margin Expansion talent ▪ Digital / WeldCloud Differentiated ▪ ▪ High Cash Conversion Experienced leaders technology ▪▪ Robotics ▪ 20%+ Attractive adjacencies ▪ aEBITDA Margin Medical & Specialty ▪ Gas Control Digital and software ▪ 100%+ 1 FCF Conversion Strong Capabilities, Vision, Momentum 21 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITAA Premier Global Fabrication Technology Company Organic Continuous Long-Term Growth Improvement Acquisitions Talent Strategic Goal Innovation Colfax Business Higher growth, higher Core values ▪▪▪▪ $3B+ System (CBS) gross margin, and lower Global Presence Attract and retain best cyclicality Revenue ▪▪ Margin Expansion talent ▪ Digital / WeldCloud Differentiated ▪ ▪ High Cash Conversion Experienced leaders technology ▪▪ Robotics ▪ 20%+ Attractive adjacencies ▪ aEBITDA Margin Medical & Specialty ▪ Gas Control Digital and software ▪ 100%+ 1 FCF Conversion Strong Capabilities, Vision, Momentum 21 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITA
We Shape the Future: Broadest Portfolio, Full Solution Set, Leading Global Brands ESAB Product Sales Mix Equipment Consumables 31% 2020 69% Most Sales Derived from Repeatable Sales of Consumable Products Best-Positioned to Meet Global Customer Needs 22 ESAB – A Fabrication Technology LeaderWe Shape the Future: Broadest Portfolio, Full Solution Set, Leading Global Brands ESAB Product Sales Mix Equipment Consumables 31% 2020 69% Most Sales Derived from Repeatable Sales of Consumable Products Best-Positioned to Meet Global Customer Needs 22 ESAB – A Fabrication Technology Leader
Diverse Global Market Supported by Favorable Secular Trends Healthcare, Other General Infrastructure Automotive & Mobile Renewable Oil & Gas Laboratory, & (Defense, Fabrication & Constr. Vehicles Machinery Energy Process Ship, Rail) $25B Market Growth Drivers Market 1,2 Welder Shortage Driving Est. Market Split : 16% 12% 6% ▪ 30% 13% 8% 5% 10% Robotics 2 Infrastructure Investment Established Markets Growing 2-3% p.a. ▪ + Advanced Materials & ▪ Medical & Specialty Digital 2nd Wave Gas Control Lightweighting Solutions Robotics Connected Devices / IoT ▪ $5B Regulatory & Safety ▪ Market Welding & Cutting ▪ Gas Management ▪ 2 Increasing Exposure to Higher Growth Segments 6-8% p.a. Positioning the Business for Higher Growth 1 23 Green indicates ESAB overweight to market or key focus area 2 ESAB – A Fabrication Technology Leader Source: ESAB Internal Analysis, IHS Markit 2021Diverse Global Market Supported by Favorable Secular Trends Healthcare, Other General Infrastructure Automotive & Mobile Renewable Oil & Gas Laboratory, & (Defense, Fabrication & Constr. Vehicles Machinery Energy Process Ship, Rail) $25B Market Growth Drivers Market 1,2 Welder Shortage Driving Est. Market Split : 16% 12% 6% ▪ 30% 13% 8% 5% 10% Robotics 2 Infrastructure Investment Established Markets Growing 2-3% p.a. ▪ + Advanced Materials & ▪ Medical & Specialty Digital 2nd Wave Gas Control Lightweighting Solutions Robotics Connected Devices / IoT ▪ $5B Regulatory & Safety ▪ Market Welding & Cutting ▪ Gas Management ▪ 2 Increasing Exposure to Higher Growth Segments 6-8% p.a. Positioning the Business for Higher Growth 1 23 Green indicates ESAB overweight to market or key focus area 2 ESAB – A Fabrication Technology Leader Source: ESAB Internal Analysis, IHS Markit 2021
Global Scale, Local Agility Drives Attractive Regional Growth and Profitability ESAB Geographic Sales Split (2020) Emerging #1 Russia Markets 50% 50% #1 Europe Developed Markets #1 China #3 North America #1 Middle (global player) East aEBITDA Margin (2020) #1 India Comparable Performance #1 South America #1 Australia Developed Emerging Markets Markets 1 Emerging Economies Expected to Grow >2.5x Developed Markets (2021-2025) 24 1 ESAB – A Fabrication Technology Leader IMF World Economic Outlook, October 2020Global Scale, Local Agility Drives Attractive Regional Growth and Profitability ESAB Geographic Sales Split (2020) Emerging #1 Russia Markets 50% 50% #1 Europe Developed Markets #1 China #3 North America #1 Middle (global player) East aEBITDA Margin (2020) #1 India Comparable Performance #1 South America #1 Australia Developed Emerging Markets Markets 1 Emerging Economies Expected to Grow >2.5x Developed Markets (2021-2025) 24 1 ESAB – A Fabrication Technology Leader IMF World Economic Outlook, October 2020
Our Playbook is Outperforming the Industry Global Share Out-Performing in 1 (2020) 2019 & 2020 Organic Innovation Engine ▪ Best-in-Class Light Industrial Equipment ▪ bps Modernized Heavy Industrial Equipment ▪ Digitally Connected Portfolio with WeldCloud ▪ Core Sales Organic Margin Improvement ~300 ▪ Growth (Avg. growth vs. peers) Rooftop Reduction ▪ Dynamic & Value Pricing ▪ Inventory Optimization ▪ Supply Chain Transformation ▪ SG&A Transformation Profit Margin % ▪ ~200 Expansion Best Team Wins – Built World-Class Team (vs. peers) ▪ Accretive Acquisitions ▪ Continuing Our Winning Strategy 25 1 ESAB – A Fabrication Technology Leader Peer group includes Lincoln Electric and welding business within ITW; core sales excluding FX and acquisitionsOur Playbook is Outperforming the Industry Global Share Out-Performing in 1 (2020) 2019 & 2020 Organic Innovation Engine ▪ Best-in-Class Light Industrial Equipment ▪ bps Modernized Heavy Industrial Equipment ▪ Digitally Connected Portfolio with WeldCloud ▪ Core Sales Organic Margin Improvement ~300 ▪ Growth (Avg. growth vs. peers) Rooftop Reduction ▪ Dynamic & Value Pricing ▪ Inventory Optimization ▪ Supply Chain Transformation ▪ SG&A Transformation Profit Margin % ▪ ~200 Expansion Best Team Wins – Built World-Class Team (vs. peers) ▪ Accretive Acquisitions ▪ Continuing Our Winning Strategy 25 1 ESAB – A Fabrication Technology Leader Peer group includes Lincoln Electric and welding business within ITW; core sales excluding FX and acquisitions
Strong Financial Performance & Resiliency 1 +200bps 7.7% 20% >100% aEBITDA Margin Improvement Sales CAGR 2020 Decremental 2020 FCF Pre-COVID (‘16-’19) Pre-COVID (‘16-’19) Margins Conversion 1 Sales, $B aEBITDA % ~17.0 - 17.5% 16.9% 16.4% 2.25 ~2.2 2.19 15.3% 15.0% 14.9% 1.95 1.94 1.80 2016 2017 2018 2019 2020 2021E 2016 2017 2018 2019 2020 2021E COVID COVID 26 1 ESAB – A Fabrication Technology Leader See appendix for non-GAAP reconciliations; Segment-level marginStrong Financial Performance & Resiliency 1 +200bps 7.7% 20% >100% aEBITDA Margin Improvement Sales CAGR 2020 Decremental 2020 FCF Pre-COVID (‘16-’19) Pre-COVID (‘16-’19) Margins Conversion 1 Sales, $B aEBITDA % ~17.0 - 17.5% 16.9% 16.4% 2.25 ~2.2 2.19 15.3% 15.0% 14.9% 1.95 1.94 1.80 2016 2017 2018 2019 2020 2021E 2016 2017 2018 2019 2020 2021E COVID COVID 26 1 ESAB – A Fabrication Technology Leader See appendix for non-GAAP reconciliations; Segment-level margin
Investing & Gaining Momentum in North American Market 1 NAM Sales Growth NAM aEBITDA % Growth Drivers Increased Pace >250 bps +20% of Innovation Rebel Warrior Cutmaster Sentinel Commercial Leveraging CBS Sales Tools ▪ Effectiveness Talent Development & Upgrade ▪ Digital Marketing Outreach ▪ Strong Channel Management ▪ Manufacturing Footprint Optimization CBS Operational ▪ Effectiveness Kaizen Led Supply Chain Transformation ▪ Dynamic Price Management ▪ 2016 2019 2016 2019 Improved Customer Experience & Engagement ▪ Running Our Playbook for Profitable Growth 27 1 ESAB – A Fabrication Technology Leader Absolute sales growth from 2016 to 2019Investing & Gaining Momentum in North American Market 1 NAM Sales Growth NAM aEBITDA % Growth Drivers Increased Pace >250 bps +20% of Innovation Rebel Warrior Cutmaster Sentinel Commercial Leveraging CBS Sales Tools ▪ Effectiveness Talent Development & Upgrade ▪ Digital Marketing Outreach ▪ Strong Channel Management ▪ Manufacturing Footprint Optimization CBS Operational ▪ Effectiveness Kaizen Led Supply Chain Transformation ▪ Dynamic Price Management ▪ 2016 2019 2016 2019 Improved Customer Experience & Engagement ▪ Running Our Playbook for Profitable Growth 27 1 ESAB – A Fabrication Technology Leader Absolute sales growth from 2016 to 2019
The Colfax Business System (CBS) is a Competitive Advantage CBS – Our Values, Processes and Tools CBS Fundamentals Voice of the Customer – Customer-Centric ▪ Pricing – Dynamic Price Management ▪ Daily Management – Delivering on Customer Commitments ▪ Standard Work – Repeatable Processes ▪ Kaizen – Continuous Improvement ▪ Problem Solving Process – Root Cause, Corrective Actions ▪ Policy Deployment – Strategic Breakthroughs ▪ Continuous We Help our The Best Innovation We Deliver Talent Development – Best Team Wins Improvement is Customers Team Wins Defines Great Results ▪ Our Way of Life Succeed Our Future the Right Way CBS Expands Capabilities, Drives Repeatable Processes, and Delivers Breakthrough Performance 28 ESAB – A Fabrication Technology LeaderThe Colfax Business System (CBS) is a Competitive Advantage CBS – Our Values, Processes and Tools CBS Fundamentals Voice of the Customer – Customer-Centric ▪ Pricing – Dynamic Price Management ▪ Daily Management – Delivering on Customer Commitments ▪ Standard Work – Repeatable Processes ▪ Kaizen – Continuous Improvement ▪ Problem Solving Process – Root Cause, Corrective Actions ▪ Policy Deployment – Strategic Breakthroughs ▪ Continuous We Help our The Best Innovation We Deliver Talent Development – Best Team Wins Improvement is Customers Team Wins Defines Great Results ▪ Our Way of Life Succeed Our Future the Right Way CBS Expands Capabilities, Drives Repeatable Processes, and Delivers Breakthrough Performance 28 ESAB – A Fabrication Technology Leader
Proven Acquisition Process Impact on ESAB Exciting Acqusitions with Strategic Fit Overarching Goals Robotic & Industrial Digital Specialty Resilient in 2020 Automation Diversification Growth Alloys Solutions MSD Acquisition Growth Revenue of Acquired Businesses, Accretive $M to GM 2019 2020 Accretive Margins in 2020 Low Cyclicality +900 bps Gross Technology Margin % Leadership Core Acquisitions Acquisitions Strengthen Our Business, Accelerate Our Performance 29 ESAB – A Fabrication Technology LeaderProven Acquisition Process Impact on ESAB Exciting Acqusitions with Strategic Fit Overarching Goals Robotic & Industrial Digital Specialty Resilient in 2020 Automation Diversification Growth Alloys Solutions MSD Acquisition Growth Revenue of Acquired Businesses, Accretive $M to GM 2019 2020 Accretive Margins in 2020 Low Cyclicality +900 bps Gross Technology Margin % Leadership Core Acquisitions Acquisitions Strengthen Our Business, Accelerate Our Performance 29 ESAB – A Fabrication Technology Leader
Acquisitions & Innovation Shifting ESAB Exposure to High-Growth Segments nd Medical & Specialty 2 Wave 1 Attractive Growth Vectors Gas Control Digital Solutions Robotics $3B+ Market $1B+ Market $1B+ Market ▪▪▪ Opportunity Opportunity $5B+ 6-8%+ MSD Growth ▪ Market Size Growth Profile Double-Digit Growth Mid-Teens Growth ▪▪ Industry-Wide ▪ Inflection Point 50%+ $300M+ Gross Expected Future Margin Sales Acquisitions of High-Growth Businesses Further Accelerate Our Performance 30 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal AnalysisAcquisitions & Innovation Shifting ESAB Exposure to High-Growth Segments nd Medical & Specialty 2 Wave 1 Attractive Growth Vectors Gas Control Digital Solutions Robotics $3B+ Market $1B+ Market $1B+ Market ▪▪▪ Opportunity Opportunity $5B+ 6-8%+ MSD Growth ▪ Market Size Growth Profile Double-Digit Growth Mid-Teens Growth ▪▪ Industry-Wide ▪ Inflection Point 50%+ $300M+ Gross Expected Future Margin Sales Acquisitions of High-Growth Businesses Further Accelerate Our Performance 30 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal Analysis
2018 Acquisition Delivering Growth and Margin Expansion Increased Exposure to Higher-Growth Markets Attractive Financial Performance Market Sales Mix 7%+ Specialty Gas Cutting & Welding Sales Control 32% Growth 30% 2018 2020 >350 bps 38% Medical & Digital aEBITDA Margin % 2018 2020 Additional Acquisition Opportunities in Adjacencies 31 ESAB – A Fabrication Technology Leader2018 Acquisition Delivering Growth and Margin Expansion Increased Exposure to Higher-Growth Markets Attractive Financial Performance Market Sales Mix 7%+ Specialty Gas Cutting & Welding Sales Control 32% Growth 30% 2018 2020 >350 bps 38% Medical & Digital aEBITDA Margin % 2018 2020 Additional Acquisition Opportunities in Adjacencies 31 ESAB – A Fabrication Technology Leader
Innovation 32 ESAB – A Fabrication Technology LeaderInnovation 32 ESAB – A Fabrication Technology Leader
ESAB – Fabrication Technology Innovation Leader nd Positioning for 2 Wave Robotic Core Business Innovations Growing Digital Offering Adoption Best-in-class new product Proprietary WeldCloud offerings Multi-brand robotics solution ▪▪▪ developments Clear value proposition to customers Leveraging ESAB’s existing portfolio ▪▪ Higher density-to-strength ratio filler ▪ Digital / software revenue stream with Breaks down barriers to welding metals and specialty alloys ▪▪ 3x core pull through robotics adoption More environmentally-centric ▪ innovations High-impact workflow solutions in ▪ complex areas Shaping the Industry Through Innovation Since 1904 33 ESAB – A Fabrication Technology LeaderESAB – Fabrication Technology Innovation Leader nd Positioning for 2 Wave Robotic Core Business Innovations Growing Digital Offering Adoption Best-in-class new product Proprietary WeldCloud offerings Multi-brand robotics solution ▪▪▪ developments Clear value proposition to customers Leveraging ESAB’s existing portfolio ▪▪ Higher density-to-strength ratio filler ▪ Digital / software revenue stream with Breaks down barriers to welding metals and specialty alloys ▪▪ 3x core pull through robotics adoption More environmentally-centric ▪ innovations High-impact workflow solutions in ▪ complex areas Shaping the Industry Through Innovation Since 1904 33 ESAB – A Fabrication Technology Leader
Accelerating Pace of Innovation New Product Introductions (#) Transforming the Portfolio Leading Medical & High-Purity Specialty Gas Control Equipment +230% 80 Lower Fume, Higher Density-to-Strength Ratio, SMART Packaging Filler Metals 24 Digitally Connected Equipment through WeldCloud 2016 2020 Modernized & Upgraded Heavy Industrial Equipment 3-year >17% ▪ 2020 Vitality 1 Index 5-year >29% Best-in-Class Light Industrial ▪ Equipment 2016 2020 Strong Vitality and Advantaged Products 34 ESAB – A Fabrication Technology Leader 1 Vitality defined as new product revenue (introduced in last 3 years or 5 years) as a percentage of total revenue Accelerating Pace of Innovation New Product Introductions (#) Transforming the Portfolio Leading Medical & High-Purity Specialty Gas Control Equipment +230% 80 Lower Fume, Higher Density-to-Strength Ratio, SMART Packaging Filler Metals 24 Digitally Connected Equipment through WeldCloud 2016 2020 Modernized & Upgraded Heavy Industrial Equipment 3-year >17% ▪ 2020 Vitality 1 Index 5-year >29% Best-in-Class Light Industrial ▪ Equipment 2016 2020 Strong Vitality and Advantaged Products 34 ESAB – A Fabrication Technology Leader 1 Vitality defined as new product revenue (introduced in last 3 years or 5 years) as a percentage of total revenue
Distinctive Products Shaping their Categories RobustFeed Renegade Rogue Portable, Long-Distance Compact, High-Powered High-Performance Professional & Industrial Wire Feeder Industrial MMA/TIG Welder Entry-Level MMA/TIG Welder Unmatched Performance: Superior wire Flexibility: Outstanding output power and High Performance: Precise, professional, §§§ feeding performance and superior protection reach, multi-voltage capabilities and consistent control for the DIY or PRO against dirt and rain user Reliability: Impact and drop resistant, ready § Unrivalled Portability: Five lifting points, for extreme temperatures in tough High Power: Efficient power block for steady §§ crane-safe lift design, ergonomic handles environments arc Customer-Centric Usability: Clear, read- Simplicity: Simple set-up, intuitive interface, High Strength & Portable: Light weight, §§§ anywhere front-panel display best-in-class weld starts compact, and robust housing design 35 ESAB – A Fabrication Technology LeaderDistinctive Products Shaping their Categories RobustFeed Renegade Rogue Portable, Long-Distance Compact, High-Powered High-Performance Professional & Industrial Wire Feeder Industrial MMA/TIG Welder Entry-Level MMA/TIG Welder Unmatched Performance: Superior wire Flexibility: Outstanding output power and High Performance: Precise, professional, §§§ feeding performance and superior protection reach, multi-voltage capabilities and consistent control for the DIY or PRO against dirt and rain user Reliability: Impact and drop resistant, ready § Unrivalled Portability: Five lifting points, for extreme temperatures in tough High Power: Efficient power block for steady §§ crane-safe lift design, ergonomic handles environments arc Customer-Centric Usability: Clear, read- Simplicity: Simple set-up, intuitive interface, High Strength & Portable: Light weight, §§§ anywhere front-panel display best-in-class weld starts compact, and robust housing design 35 ESAB – A Fabrication Technology Leader
CBS Accelerating Product Innovation Strategic Planning 3-Year Roadmap & Stage-Gate Commercial Cycle Budget Prioritization Execution Ramp-up Prioritization Across Regions Stage Gates & Checklists Business Line Review Marcom Launch Material ▪▪ ▪▪ and Product Lines Business Case Creation Market Sizing & SWOT▪ Demo & Initial Success Stories ▪▪ R&D Centers of Excellence ▪ Rapid Prototyping and ▪ Competitive Landscape & Point Sales Training ▪▪ Open Innovation with Strategic Validation with Customers ▪ of Differentiation Mapping Partners Key Performance Indicators ▪ Cross-Functional Team ▪ Voice of Customers Insights ▪ Budget Planning and Tracking Reviews ▪ Structured Process Focused on Customer Needs and Speed to Market 36 ESAB – A Fabrication Technology LeaderCBS Accelerating Product Innovation Strategic Planning 3-Year Roadmap & Stage-Gate Commercial Cycle Budget Prioritization Execution Ramp-up Prioritization Across Regions Stage Gates & Checklists Business Line Review Marcom Launch Material ▪▪ ▪▪ and Product Lines Business Case Creation Market Sizing & SWOT▪ Demo & Initial Success Stories ▪▪ R&D Centers of Excellence ▪ Rapid Prototyping and ▪ Competitive Landscape & Point Sales Training ▪▪ Open Innovation with Strategic Validation with Customers ▪ of Differentiation Mapping Partners Key Performance Indicators ▪ Cross-Functional Team ▪ Voice of Customers Insights ▪ Budget Planning and Tracking Reviews ▪ Structured Process Focused on Customer Needs and Speed to Market 36 ESAB – A Fabrication Technology Leader
Digital Solutions Introduction Video https://vimeo.com/520960765/ec6534ea3c ▪ 37 ESAB – A Fabrication Technology LeaderDigital Solutions Introduction Video https://vimeo.com/520960765/ec6534ea3c ▪ 37 ESAB – A Fabrication Technology Leader
Digital Solutions is a Game-Changer for our Customers and ESAB Customer: Connected Devices (#) Insights Into Efficiency of Operations ▪ “Our arc time factor increased 50% Arc-Time / Deposition Rate ▪ with WeldCloud.” – Mobile Machinery Welding Time Per Operator ▪ Mfr. (Poland) Material Consumption +90% ▪ Quality & Traceability Metrics ▪ “We mitigated $3M in risk of rework due to non-compliance.” – Pressure Fleet Management ▪ Vessel Mfr. (Brazil) Remote Monitoring ▪ Reduced Equipment Downtime 2019 2020 Potential ▪ ESAB: Long-Term Benefits to ESAB Positions as a Solution Provider vs. Material Supplier ▪ 3X Distinctively Connects Our Portfolio ▪ Provides Unique User Insights and Analytics ▪ $100M in Projected New High-Margin Recurring Revenue Stream & Pull-Through ▪ 1 Additional Revenues Opportunities Traditional Lifecycle Value w/ Access to New Customers Equipment WC Connected ▪ Sales Solutions Digital Solutions Technology Core to our Innovation 38 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal AnalysisDigital Solutions is a Game-Changer for our Customers and ESAB Customer: Connected Devices (#) Insights Into Efficiency of Operations ▪ “Our arc time factor increased 50% Arc-Time / Deposition Rate ▪ with WeldCloud.” – Mobile Machinery Welding Time Per Operator ▪ Mfr. (Poland) Material Consumption +90% ▪ Quality & Traceability Metrics ▪ “We mitigated $3M in risk of rework due to non-compliance.” – Pressure Fleet Management ▪ Vessel Mfr. (Brazil) Remote Monitoring ▪ Reduced Equipment Downtime 2019 2020 Potential ▪ ESAB: Long-Term Benefits to ESAB Positions as a Solution Provider vs. Material Supplier ▪ 3X Distinctively Connects Our Portfolio ▪ Provides Unique User Insights and Analytics ▪ $100M in Projected New High-Margin Recurring Revenue Stream & Pull-Through ▪ 1 Additional Revenues Opportunities Traditional Lifecycle Value w/ Access to New Customers Equipment WC Connected ▪ Sales Solutions Digital Solutions Technology Core to our Innovation 38 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal Analysis
Software & Digital Acquisitions Enabling Robotics Adoption Octopuz OLP Software the Latest Addition to Total Solution Long-Term Benefits to ESAB Recurring Software Sales Complex Part Programming Made Simple ▪ Robotic Pull-Through Purus Robotic Programming Works with any Robot-OEM in the Factory ▪ Filler Metal Software $50-100M in Applies to High-Mix / Low-Volume Production ▪ Projected Reduced Robot Downtime ▪ Additional Increased Repeatability, Quality and Productivity ▪ 1 Revenues ’20 ’21 ’22 ’23 ’24 ’25 Increases Addressable Market by >$1B ▪ Synergies with Digital Solutions ▪ WeldCloud + NxG TBi Robotic Torch + Enables Pull-Through of Filler Metal and ▪ Equipment HKS quality Equipment Sales Accelerating the Pace of Robotic Adoption 39 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal AnalysisSoftware & Digital Acquisitions Enabling Robotics Adoption Octopuz OLP Software the Latest Addition to Total Solution Long-Term Benefits to ESAB Recurring Software Sales Complex Part Programming Made Simple ▪ Robotic Pull-Through Purus Robotic Programming Works with any Robot-OEM in the Factory ▪ Filler Metal Software $50-100M in Applies to High-Mix / Low-Volume Production ▪ Projected Reduced Robot Downtime ▪ Additional Increased Repeatability, Quality and Productivity ▪ 1 Revenues ’20 ’21 ’22 ’23 ’24 ’25 Increases Addressable Market by >$1B ▪ Synergies with Digital Solutions ▪ WeldCloud + NxG TBi Robotic Torch + Enables Pull-Through of Filler Metal and ▪ Equipment HKS quality Equipment Sales Accelerating the Pace of Robotic Adoption 39 1 ESAB – A Fabrication Technology Leader Source: based on ESAB Internal Analysis
Financial Performance 40 ESAB – A Fabrication Technology LeaderFinancial Performance 40 ESAB – A Fabrication Technology Leader
CBS Driving Operational Excellence Price Change (%) Highlights – Improvements 2016 to 2020 5% 3% 1% 1% Dynamic Price/Cost Management ▪ 2016 2017 2018 2019 2020 -2% Delivered $33M in Footprint Savings ▪ Working Capital Improved by >1/2 Turn ▪ Manufacturing Footprint Reduction (# Facilities) 45 Improved O2C Processes ▪ 31 27 Enhanced Inventory Management ▪ 2016 2020 2021E Future Vendor Term Renegotiations ▪ Working Capital Turns Improvement Substantial Opportunities to Drive Further Improvements ▪ Through Kaizens 5.5x 5.1x 4.4x 2016 2020 2021E Future Continuously Improving our Operational Capabilities 41 ESAB – A Fabrication Technology LeaderCBS Driving Operational Excellence Price Change (%) Highlights – Improvements 2016 to 2020 5% 3% 1% 1% Dynamic Price/Cost Management ▪ 2016 2017 2018 2019 2020 -2% Delivered $33M in Footprint Savings ▪ Working Capital Improved by >1/2 Turn ▪ Manufacturing Footprint Reduction (# Facilities) 45 Improved O2C Processes ▪ 31 27 Enhanced Inventory Management ▪ 2016 2020 2021E Future Vendor Term Renegotiations ▪ Working Capital Turns Improvement Substantial Opportunities to Drive Further Improvements ▪ Through Kaizens 5.5x 5.1x 4.4x 2016 2020 2021E Future Continuously Improving our Operational Capabilities 41 ESAB – A Fabrication Technology Leader
SG&A Transformation Project Savings SG&A Cumulative Savings, $M Digitizing Internal Processes Using Process Data Mining Analytics to Drive Efficiencies ▪ $14M+ Leveraging Lower-Cost Global Shared Service Center ▪ Footprint 25-30 Improving Organizational Effectiveness, Eliminating ▪ Duplicative Activties 11 Renegotiated Vendor Rates & Implemented Technology to ▪ Improve Policy Compliance 2020 2021E Future Leveraging Technology and Global Scale to Reduce SG&A 42 ESAB – A Fabrication Technology LeaderSG&A Transformation Project Savings SG&A Cumulative Savings, $M Digitizing Internal Processes Using Process Data Mining Analytics to Drive Efficiencies ▪ $14M+ Leveraging Lower-Cost Global Shared Service Center ▪ Footprint 25-30 Improving Organizational Effectiveness, Eliminating ▪ Duplicative Activties 11 Renegotiated Vendor Rates & Implemented Technology to ▪ Improve Policy Compliance 2020 2021E Future Leveraging Technology and Global Scale to Reduce SG&A 42 ESAB – A Fabrication Technology Leader
CBS Improving Cash Flow Capabilities 1 Segment Operating Free Cash Conversion Key Highlights 2020 Working Capital Tailwind, 2021 Headwind >100% ▪ Supply Chain Transformation Supporting Lower Working ▪ 100%+ 90-100% Capital 90% Improved Inventory Management ▪ 70% Digitizing Processes ▪ Improving Order to Cash & Purchase to Pay ▪ Substantial Opportunity Remains ▪ Drive Further Inventory Management Improvements ▪ Roll-Out Supplier Financing Program Globally ▪ 2018 2019 2020 2021E Future Higher / More Consistent Cash Flow 43 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITACBS Improving Cash Flow Capabilities 1 Segment Operating Free Cash Conversion Key Highlights 2020 Working Capital Tailwind, 2021 Headwind >100% ▪ Supply Chain Transformation Supporting Lower Working ▪ 100%+ 90-100% Capital 90% Improved Inventory Management ▪ 70% Digitizing Processes ▪ Improving Order to Cash & Purchase to Pay ▪ Substantial Opportunity Remains ▪ Drive Further Inventory Management Improvements ▪ Roll-Out Supplier Financing Program Globally ▪ 2018 2019 2020 2021E Future Higher / More Consistent Cash Flow 43 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITA
A Better, Stronger ESAB Sales Growth Bridge, $B MSD Sales Growth 1-2% ▪ $3+ 1-2% CAGR 2-3% CAGR Leverage CBS Growth Tools ▪ CAGR Launch Innovative New Product Introductions ▪ ~$2.2 Execute Attractive Acquisitions ▪ 2021E Market Innovation Accelerators M&A Long-Term Strategic Goal Segment-Level aEBITDA Margin % Bridge >250bps Margin Expansion ▪ Sales Growth ▪ 20%+ Further Plant Footprint Rationlization ▪ 17-17.5% Continue SG&A Transformation ▪ Deliver Productivity and Sourcing Improvements ▪ 2021E Market Innovation Accelerators M&A CBS Business Long-Term Continued Investment in ESAB ▪ Initiatives Investment Strategic Goal Delivering Sustained Growth, Innovation, and Margin Expansion 44 ESAB – A Fabrication Technology LeaderA Better, Stronger ESAB Sales Growth Bridge, $B MSD Sales Growth 1-2% ▪ $3+ 1-2% CAGR 2-3% CAGR Leverage CBS Growth Tools ▪ CAGR Launch Innovative New Product Introductions ▪ ~$2.2 Execute Attractive Acquisitions ▪ 2021E Market Innovation Accelerators M&A Long-Term Strategic Goal Segment-Level aEBITDA Margin % Bridge >250bps Margin Expansion ▪ Sales Growth ▪ 20%+ Further Plant Footprint Rationlization ▪ 17-17.5% Continue SG&A Transformation ▪ Deliver Productivity and Sourcing Improvements ▪ 2021E Market Innovation Accelerators M&A CBS Business Long-Term Continued Investment in ESAB ▪ Initiatives Investment Strategic Goal Delivering Sustained Growth, Innovation, and Margin Expansion 44 ESAB – A Fabrication Technology Leader
Talent & Summary 45 ESAB – A Fabrication Technology LeaderTalent & Summary 45 ESAB – A Fabrication Technology Leader
Best Team Wins: ESAB Leadership Shyam Kambeyanda Chief Executive Officer Regional Leadership Functional Leadership Olivier Biebuyck Billal Hammoud Kevin Johnson Larry Coble President, EMEAR, President, Americas Chief Financial Officer Senior Vice President, Equipment and Digital Solutions and Fabrication Solutions Supply Chain and CBS Johan Fransson Walter Freitas Michele Campion Scott Grisham Managing Director, Managing Director, Vice President, Vice President, Business Europe South America Human Resources Development Isa Sanad Rohit Gambhir Curtis Jewell Tilea Coleman Managing Director, Managing Director, General Counsel Vice President, MEA India Corporate Communications Michal Kozlowski Stanley Chew Steve Molenda Managing Director, Managing Director, Sr. Director, E. Europe, Russia, CIS Asia Global MarCom Experienced and Diverse Team of Leaders Across the World 46 ESAB – A Fabrication Technology LeaderBest Team Wins: ESAB Leadership Shyam Kambeyanda Chief Executive Officer Regional Leadership Functional Leadership Olivier Biebuyck Billal Hammoud Kevin Johnson Larry Coble President, EMEAR, President, Americas Chief Financial Officer Senior Vice President, Equipment and Digital Solutions and Fabrication Solutions Supply Chain and CBS Johan Fransson Walter Freitas Michele Campion Scott Grisham Managing Director, Managing Director, Vice President, Vice President, Business Europe South America Human Resources Development Isa Sanad Rohit Gambhir Curtis Jewell Tilea Coleman Managing Director, Managing Director, General Counsel Vice President, MEA India Corporate Communications Michal Kozlowski Stanley Chew Steve Molenda Managing Director, Managing Director, Sr. Director, E. Europe, Russia, CIS Asia Global MarCom Experienced and Diverse Team of Leaders Across the World 46 ESAB – A Fabrication Technology Leader
The Best Team Wins OUR GOAL OUR RESULTS Accountable Leaders Drive Results HIGH PERFORMING, DIVERSE, AND INCLUSIVE WORKPLACE OUR STRATEGY OUR CULTURE Our Associates Believe in ESAB – 84% Overall Engagement in Annual Survey Creating Better Together ATTRACT THE BEST TALENT Committed Team – MSD Voluntary Turnover DEVELOP OUR 1 TALENT Best in Class Safety Performance (TRIR) 0.97 0.70 0.65 RETAIN OUR 0.42 0.34 TALENT 2016 2017 2018 2019 2020 47 1 ESAB – A Fabrication Technology Leader Total Recordable Incident Rate (TRIR)The Best Team Wins OUR GOAL OUR RESULTS Accountable Leaders Drive Results HIGH PERFORMING, DIVERSE, AND INCLUSIVE WORKPLACE OUR STRATEGY OUR CULTURE Our Associates Believe in ESAB – 84% Overall Engagement in Annual Survey Creating Better Together ATTRACT THE BEST TALENT Committed Team – MSD Voluntary Turnover DEVELOP OUR 1 TALENT Best in Class Safety Performance (TRIR) 0.97 0.70 0.65 RETAIN OUR 0.42 0.34 TALENT 2016 2017 2018 2019 2020 47 1 ESAB – A Fabrication Technology Leader Total Recordable Incident Rate (TRIR)
A Premier Global Fabrication Technology Company Long-Term Strategic Goal Resilient Business with Strong Financial Performance ▪ $3B+ Organic Growth Driven By: ▪ Revenue Innovation Leadership ▪ Strong Regional Sales Teams ▪ Strong CBS Foundation, Significant Margin Expansion Opportunities ▪ Shaping the Business Towards Low-Cyclicality, Higher-Margin and Higher-Growth ▪ 20%+ aEBITDA Margin Advancing Our Strategy ▪ Digital through WeldCloud ▪ Robotics through Workflow Solutions & Core-Products Pull-Through ▪ Acquiring into Attractive Adjacencies & Differentiated Technologies ▪ 100%+ Talent – Best Team Wins! ▪ 1 FCF Conversion 48 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITAA Premier Global Fabrication Technology Company Long-Term Strategic Goal Resilient Business with Strong Financial Performance ▪ $3B+ Organic Growth Driven By: ▪ Revenue Innovation Leadership ▪ Strong Regional Sales Teams ▪ Strong CBS Foundation, Significant Margin Expansion Opportunities ▪ Shaping the Business Towards Low-Cyclicality, Higher-Margin and Higher-Growth ▪ 20%+ aEBITDA Margin Advancing Our Strategy ▪ Digital through WeldCloud ▪ Robotics through Workflow Solutions & Core-Products Pull-Through ▪ Acquiring into Attractive Adjacencies & Differentiated Technologies ▪ 100%+ Talent – Best Team Wins! ▪ 1 FCF Conversion 48 1 ESAB – A Fabrication Technology Leader FCF Conversion is on a segment basis, unlevered. Calculated as FCF divided by aEBITA
Q&AQ&A
MedTechCo Introduction March 11, 2021MedTechCo Introduction March 11, 2021
Presenters Today Matt Trerotola Brady Shirley CEO President & COO MedTechCo MedTechCo Ben Berry Louis Vogt Steve Ingel Chief Financial President and EVP, Healthcare Officer, DJO GM, Surgical Solutions 52Presenters Today Matt Trerotola Brady Shirley CEO President & COO MedTechCo MedTechCo Ben Berry Louis Vogt Steve Ingel Chief Financial President and EVP, Healthcare Officer, DJO GM, Surgical Solutions 52
Specialty MedTech Innovator Built on a Strong Foundation… Long-term Strategic Goals Well Positioned Specialty Underpinned By Colfax MedTech Company Continuous Improvement Clear Strategy To Deliver HSD ▪ Foundation in Orthopedics Core Growth ▪ Proven innovation engine ▪ Operational improvement ▪ Attractive positions ▪ Leading with software ▪ Accelerated innovation workflow solutions Mid-60s ▪ Strong momentum ▪ Bolt-on acquisitions ▪ Full M&A pipeline Gross Margin ▪ Experienced MedTech team >25% 1 aEBITDA Margin …Uniquely Positioned for Significant Value Creation 53 1 Segment-level margin Specialty MedTech Innovator Built on a Strong Foundation… Long-term Strategic Goals Well Positioned Specialty Underpinned By Colfax MedTech Company Continuous Improvement Clear Strategy To Deliver HSD ▪ Foundation in Orthopedics Core Growth ▪ Proven innovation engine ▪ Operational improvement ▪ Attractive positions ▪ Leading with software ▪ Accelerated innovation workflow solutions Mid-60s ▪ Strong momentum ▪ Bolt-on acquisitions ▪ Full M&A pipeline Gross Margin ▪ Experienced MedTech team >25% 1 aEBITDA Margin …Uniquely Positioned for Significant Value Creation 53 1 Segment-level margin
Recognized as a Global Leader across Orthopedics 2021E REVENUE SPLIT (~$1.4B) WHAT DISTINGUISHES MEDTECHCO? ROW 7% • FAST GROWING RECONSTRUCTIVE PLATFORM Reconstructive (Recon) reshaping portfolio 25% Europe 20% 75% Prevention & • GLOBAL LEADER IN PREVENTION & United States Recovery (P&R) 73% RECOVERY with opportunities to expand Recon By Segment By Region • Only major player with meaningful share across the ORTHO CARE CONTINUUM Industry Leading Brands • Anchored in INDUSTRY-DEFINING PRODUCTS and solutions 54Recognized as a Global Leader across Orthopedics 2021E REVENUE SPLIT (~$1.4B) WHAT DISTINGUISHES MEDTECHCO? ROW 7% • FAST GROWING RECONSTRUCTIVE PLATFORM Reconstructive (Recon) reshaping portfolio 25% Europe 20% 75% Prevention & • GLOBAL LEADER IN PREVENTION & United States Recovery (P&R) 73% RECOVERY with opportunities to expand Recon By Segment By Region • Only major player with meaningful share across the ORTHO CARE CONTINUUM Industry Leading Brands • Anchored in INDUSTRY-DEFINING PRODUCTS and solutions 54
Addressing Big, Attractive Ortho Market… 1 2 2019 INDUSTRY SALES ($B) TOP ORTHO PLAYERS ($B) MedTechCo competes in half of the $53B DePuy Synthes 8.8 Orthopedics market and “touches” it all 2020E-2025E 1 Industry CAGR Zimmer Biomet 7.3 ~48 5 ~4% Stryker 6.3 9 Knee 3-4% Smith & Nephew 3.6 Joint Recon Hip 8 Medtronic 2.7 3 Extremities 7-8% P&R market Arthrex 2.6 growth: 3-4% MedTechCo in 10 Spine competitive position MedTechCo DJO 1.2 3-4% to capture market 7 Trauma share Nuvasive 1.2 Sports Medicine 6 5-6% Aesculap 0.7 Biologics 5 2-4% 3 Surgical implants Prevention & Rehabilitation Wright 0.7 and Instrumentation Devices MedTechCo is Positioned for Share Gain and Expansion 1 Source: based on internal Medtech analysis 2 55 2019 sales per public filings; MedTechCo 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019 3 Acquired by Stryker in 2020Addressing Big, Attractive Ortho Market… 1 2 2019 INDUSTRY SALES ($B) TOP ORTHO PLAYERS ($B) MedTechCo competes in half of the $53B DePuy Synthes 8.8 Orthopedics market and “touches” it all 2020E-2025E 1 Industry CAGR Zimmer Biomet 7.3 ~48 5 ~4% Stryker 6.3 9 Knee 3-4% Smith & Nephew 3.6 Joint Recon Hip 8 Medtronic 2.7 3 Extremities 7-8% P&R market Arthrex 2.6 growth: 3-4% MedTechCo in 10 Spine competitive position MedTechCo DJO 1.2 3-4% to capture market 7 Trauma share Nuvasive 1.2 Sports Medicine 6 5-6% Aesculap 0.7 Biologics 5 2-4% 3 Surgical implants Prevention & Rehabilitation Wright 0.7 and Instrumentation Devices MedTechCo is Positioned for Share Gain and Expansion 1 Source: based on internal Medtech analysis 2 55 2019 sales per public filings; MedTechCo 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019 3 Acquired by Stryker in 2020
…Fueled by Secular Growth and Technology Trends Aging, but active Transitioning to Innovation improving the Growing healthcare population, rising obesity outpatient care pathways quality of care consumerism ▪ Aging population ▪ Shift to ambulatory surgical centers ▪ Digital offerings, minimally invasive ▪ Consumers more informed and (ASCs) / outpatient settings surgery involved ▪ Increasingly active lifestyles ▪ Hospitals expanding into primary ▪ Computer Assisted Surgery ▪ Rise of telehealth & digital health ▪ Rising obesity clinics CAS/Robotics growth 56…Fueled by Secular Growth and Technology Trends Aging, but active Transitioning to Innovation improving the Growing healthcare population, rising obesity outpatient care pathways quality of care consumerism ▪ Aging population ▪ Shift to ambulatory surgical centers ▪ Digital offerings, minimally invasive ▪ Consumers more informed and (ASCs) / outpatient settings surgery involved ▪ Increasingly active lifestyles ▪ Hospitals expanding into primary ▪ Computer Assisted Surgery ▪ Rise of telehealth & digital health ▪ Rising obesity clinics CAS/Robotics growth 56
Fast-Growing Recon Business with Proven Playbook 1 RECON SALES & MARKET POSITION U.S. RECONSTRUCTIVE CORE SALES GROWTH (CAGR) $20B market expected to grow 4-5% per year (Extremity segment expected to grow 7-8% per year) +17% Foot & Ankle Hip Reverse #1 Shoulder US in 2 ~$0.35B #3 Shoulder 2015 2016 2017 2018 2019 Shoulder Market growth Knee 5x Hip/Knee PROVEN PLAYBOOK, ABOVE MARKET GROWTH Majority of sales in fast growing Extremities segment ▪ Superior clinical outcomes ▪ Industry leading Key Opinion Leader (KOL) teams Pioneered U.S. transition from Anatomic to Reverse shoulder ▪ Unmatched innovation cadence Large global expansion opportunity: 94% US Sales ▪ Best-in-class medical education platform ▪ DonJoy brand and contracting power 1 Source: based on internal Medtech analysis 57 2 2021 sales estimates Fast-Growing Recon Business with Proven Playbook 1 RECON SALES & MARKET POSITION U.S. RECONSTRUCTIVE CORE SALES GROWTH (CAGR) $20B market expected to grow 4-5% per year (Extremity segment expected to grow 7-8% per year) +17% Foot & Ankle Hip Reverse #1 Shoulder US in 2 ~$0.35B #3 Shoulder 2015 2016 2017 2018 2019 Shoulder Market growth Knee 5x Hip/Knee PROVEN PLAYBOOK, ABOVE MARKET GROWTH Majority of sales in fast growing Extremities segment ▪ Superior clinical outcomes ▪ Industry leading Key Opinion Leader (KOL) teams Pioneered U.S. transition from Anatomic to Reverse shoulder ▪ Unmatched innovation cadence Large global expansion opportunity: 94% US Sales ▪ Best-in-class medical education platform ▪ DonJoy brand and contracting power 1 Source: based on internal Medtech analysis 57 2 2021 sales estimates
Market Leader in Prevention & Recovery with Iconic Brands 1 P&R SALES & MARKET POSITION MARKET LEADERSHIP • Superior clinical outcomes $5B market expected to grow 3-4% per year • Leader in fast growing Sports Medicine segment Footcare Globally • Strong contract position across all GPOs #1 in Bracing • Leader in therapy modalities strengthened by Litecure™ Globally Recovery 2 ~$1.0B #1 in Rehab Sciences US in TECHNOLOGY LEADERSHIP #1 Diabetic Bracing Footcare Industry-defining products across the Ortho continuum MotionMD workflow software solution drives 40% of US Clinics Deep penetration in global markets: 34% ex-US Sales ® ® ® ® ® DonJoy Aircast DonJoy Advantage Chattanooga ProCare 1 Source: based on internal Medtech analysis 58 2 2021 sales estimates Market Leader in Prevention & Recovery with Iconic Brands 1 P&R SALES & MARKET POSITION MARKET LEADERSHIP • Superior clinical outcomes $5B market expected to grow 3-4% per year • Leader in fast growing Sports Medicine segment Footcare Globally • Strong contract position across all GPOs #1 in Bracing • Leader in therapy modalities strengthened by Litecure™ Globally Recovery 2 ~$1.0B #1 in Rehab Sciences US in TECHNOLOGY LEADERSHIP #1 Diabetic Bracing Footcare Industry-defining products across the Ortho continuum MotionMD workflow software solution drives 40% of US Clinics Deep penetration in global markets: 34% ex-US Sales ® ® ® ® ® DonJoy Aircast DonJoy Advantage Chattanooga ProCare 1 Source: based on internal Medtech analysis 58 2 2021 sales estimates
Unique Position Across Full Care Continuum PREVENTION REPAIR RECOVERY PERFORMANCE PREVENTION SURGICAL RECOVERY REHAB • Athletic braces • Pre-op braces • Shoulders • Post-op braces • Traction devices • Slings • Bone growth stim. • Muscle stimulation • Knees • Electrotherapy • Protective solutions • DVT • Hips • Laser therapy • Orthotic shoes • Cold therapy • Foot/Ankle • Heat/cold therapy • Brand leverage with hospitals, surgeons, clinicians, patients STRATEGIC • Digital workflow solutions for clinics ADVANTAGES • Connected medicine solutions for patient journey • ASC, Bundled Care partner in full episode of care Leveraging Access and Technology for Strategic Advantage 59Unique Position Across Full Care Continuum PREVENTION REPAIR RECOVERY PERFORMANCE PREVENTION SURGICAL RECOVERY REHAB • Athletic braces • Pre-op braces • Shoulders • Post-op braces • Traction devices • Slings • Bone growth stim. • Muscle stimulation • Knees • Electrotherapy • Protective solutions • DVT • Hips • Laser therapy • Orthotic shoes • Cold therapy • Foot/Ankle • Heat/cold therapy • Brand leverage with hospitals, surgeons, clinicians, patients STRATEGIC • Digital workflow solutions for clinics ADVANTAGES • Connected medicine solutions for patient journey • ASC, Bundled Care partner in full episode of care Leveraging Access and Technology for Strategic Advantage 59
Company has Evolved, Growth is Accelerating 1 Pre-Colfax Colfax Future CORE REVENUE 2% 4% HSD GROWTH Consistently 2016-2018 CAGR 2019 MARGIN 19% 22% ~25%+ (aEBITDA) 2016 2019 Future Recon P&R Recon P&R Recon P&R REVENUE 2 MIX 16 25+ (% of revenue) 2020 Future 2016 P&R Recon Recon P&R Recon P&R 3 VITALITY 7% 30%+ 11% 20%+ 30%+ 30%+ (% of revenue) 2018 2020 Future • Improving NPI process NEW PRODUCT • Broadened surgical offering • Continued surgical expansion • High performing NPI capability DEVELOPMENT • Began rebuilding P&R NPI • Accelerating # of P&R launches 1 See appendix for non-GAAP reconciliations, 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019 2 Mix shown reflects business realignment of Bone Growth Stimulation now included within Preventative and Rehabilitation 60 3 Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue Company has Evolved, Growth is Accelerating 1 Pre-Colfax Colfax Future CORE REVENUE 2% 4% HSD GROWTH Consistently 2016-2018 CAGR 2019 MARGIN 19% 22% ~25%+ (aEBITDA) 2016 2019 Future Recon P&R Recon P&R Recon P&R REVENUE 2 MIX 16 25+ (% of revenue) 2020 Future 2016 P&R Recon Recon P&R Recon P&R 3 VITALITY 7% 30%+ 11% 20%+ 30%+ 30%+ (% of revenue) 2018 2020 Future • Improving NPI process NEW PRODUCT • Broadened surgical offering • Continued surgical expansion • High performing NPI capability DEVELOPMENT • Began rebuilding P&R NPI • Accelerating # of P&R launches 1 See appendix for non-GAAP reconciliations, 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019 2 Mix shown reflects business realignment of Bone Growth Stimulation now included within Preventative and Rehabilitation 60 3 Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue
Momentum Powered by Colfax Improvement Pillars 50% evolution of Executive Reduced backorders in P&R by Continuous Talent + Leadership Team and 83% overall 56% and improved held orders ✓✓ Improvement Organization associate engagement (+20% vs. by 29% (1Q20 v. 4Q18) prior year) Increased investment in innovation Completed 6 bolt-on Strategy + Acquisitions acquisitions in the last led to 300% increase in new ✓ ✓ Innovation 12 months launches 2020 vs. 2017 CBS Journey Underway and Accelerating 61Momentum Powered by Colfax Improvement Pillars 50% evolution of Executive Reduced backorders in P&R by Continuous Talent + Leadership Team and 83% overall 56% and improved held orders ✓✓ Improvement Organization associate engagement (+20% vs. by 29% (1Q20 v. 4Q18) prior year) Increased investment in innovation Completed 6 bolt-on Strategy + Acquisitions acquisitions in the last led to 300% increase in new ✓ ✓ Innovation 12 months launches 2020 vs. 2017 CBS Journey Underway and Accelerating 61
The Best Team Wins CREATING BETTER TOGETHER ▪ Strong combination of MedTech leadership ATTRACT THE and Colfax talent BEST TALENT ▪ Group structure in place for strategic expansion ▪ Leadership Development Programs DEVELOP OUR TALENT ▪ Commercial / Operations Bootcamps ▪ 20% Improvement in 2020 Engagement Score 83% overall engagement RETAIN OUR ▪ Enterprise-wide focus on D&I opportunities TALENT ▪ Acting on talent feedback to drive continuous improvement MedTechCo Talent Forms the Backbone of Our Success 62The Best Team Wins CREATING BETTER TOGETHER ▪ Strong combination of MedTech leadership ATTRACT THE and Colfax talent BEST TALENT ▪ Group structure in place for strategic expansion ▪ Leadership Development Programs DEVELOP OUR TALENT ▪ Commercial / Operations Bootcamps ▪ 20% Improvement in 2020 Engagement Score 83% overall engagement RETAIN OUR ▪ Enterprise-wide focus on D&I opportunities TALENT ▪ Acting on talent feedback to drive continuous improvement MedTechCo Talent Forms the Backbone of Our Success 62
Strong Leadership Team, Deep Med Tech Experience Brady Shirley Ben Berry President & COO Chief Financial MedTechCo Officer, DJO Stryker, IMDS Alcon Winning Team of Seasoned Professionals Steve Ingel Kevin Cordell Louis Vogt Andrew Fox-Smith EVP, Healthcare President and Group President, President, Solutions Prevention & Recovery GM, Surgical International Business Smith & Nephew Wright Medical Zimmer Biomet Stryker Jason Anderson Tony Stallings Ken Konopa Gary Justak President, Senior Vice President, Senior Vice President, President, Bracing and Supports Supply Chain CBS & Growth Foot & Ankle BASF, Saint-Gobain Honeywell, Boston Scientific Colfax, Danaher Stryker Ruba Sarris-Sawaya Jim Pomeroy Raj Subramonian Terry Ross Vice President, Vice President of Quality Senior Vice President President, Clinical Affairs Assurance & Regulatory Affairs & GM, Footcare Solutions Recovery Sciences Medtronic Stryker Dell Colfax, Danaher Italics: Previous experience 63Strong Leadership Team, Deep Med Tech Experience Brady Shirley Ben Berry President & COO Chief Financial MedTechCo Officer, DJO Stryker, IMDS Alcon Winning Team of Seasoned Professionals Steve Ingel Kevin Cordell Louis Vogt Andrew Fox-Smith EVP, Healthcare President and Group President, President, Solutions Prevention & Recovery GM, Surgical International Business Smith & Nephew Wright Medical Zimmer Biomet Stryker Jason Anderson Tony Stallings Ken Konopa Gary Justak President, Senior Vice President, Senior Vice President, President, Bracing and Supports Supply Chain CBS & Growth Foot & Ankle BASF, Saint-Gobain Honeywell, Boston Scientific Colfax, Danaher Stryker Ruba Sarris-Sawaya Jim Pomeroy Raj Subramonian Terry Ross Vice President, Vice President of Quality Senior Vice President President, Clinical Affairs Assurance & Regulatory Affairs & GM, Footcare Solutions Recovery Sciences Medtronic Stryker Dell Colfax, Danaher Italics: Previous experience 63
Clear Strategy to Deliver Long-term Growth Powerful combination of product and solution innovation, proactively addressing key market trends with acquisitions as accelerator 2 5 1 3 4 Accelerate Lead in Digital Rapid growth in Expand through Win in the ASC Innovation Healthcare Foot & Ankle M&A Delivering Superior Clinical Outcomes Accelerating from MSD+ to HSD Organic Growth 64Clear Strategy to Deliver Long-term Growth Powerful combination of product and solution innovation, proactively addressing key market trends with acquisitions as accelerator 2 5 1 3 4 Accelerate Lead in Digital Rapid growth in Expand through Win in the ASC Innovation Healthcare Foot & Ankle M&A Delivering Superior Clinical Outcomes Accelerating from MSD+ to HSD Organic Growth 64
1 Accelerated Innovation Driving Core Growth… NEW PRODUCT INTRODUCTIONS Strategic expansion of surgical market coverage +300% 32 Expanding BAS leadership 8 into high growth categories 2017 2020 Leadership in transition to modalities in Recovery Sciences 1 P&R Vitality 11% Index (3Y) (2020) 7% in 2018 Rapid growth of F&A with surgical innovation cadence playbook Reconstructive 1 Vitality Index 30+% (3Y) (2020) 2018 2021 Progress and Pipeline to Hold 30%+ Recon Vitality and Drive to 20% Goal in P&R 65 1 Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue 1 Accelerated Innovation Driving Core Growth… NEW PRODUCT INTRODUCTIONS Strategic expansion of surgical market coverage +300% 32 Expanding BAS leadership 8 into high growth categories 2017 2020 Leadership in transition to modalities in Recovery Sciences 1 P&R Vitality 11% Index (3Y) (2020) 7% in 2018 Rapid growth of F&A with surgical innovation cadence playbook Reconstructive 1 Vitality Index 30+% (3Y) (2020) 2018 2021 Progress and Pipeline to Hold 30%+ Recon Vitality and Drive to 20% Goal in P&R 65 1 Vitality defined as new product revenue (introduced in last 3 years) as a percentage of total revenue
1 …and Accelerating Key Strategies ® AltiVate Anatomic CS Edge™ EMPOWR Partial Knee™ Stemless Shoulder Implant NextGen Uni Knee ® ▪ Expands Altivate® Anatomic in fastest ▪ Empowr expansion into high growth growing shoulder segment segment ▪ Design optimized for younger patients ▪ Ideal procedure for ASC environment ® ® ▪ Enhanced repeatability w/ Drop-And-Go▪ Unique Empowr articulation 2 ▪ Tri-fin + P best in class fixation▪ One-tray instrumentation system ▪ One-tray instrumentation ideal for ASC 661 …and Accelerating Key Strategies ® AltiVate Anatomic CS Edge™ EMPOWR Partial Knee™ Stemless Shoulder Implant NextGen Uni Knee ® ▪ Expands Altivate® Anatomic in fastest ▪ Empowr expansion into high growth growing shoulder segment segment ▪ Design optimized for younger patients ▪ Ideal procedure for ASC environment ® ® ▪ Enhanced repeatability w/ Drop-And-Go▪ Unique Empowr articulation 2 ▪ Tri-fin + P best in class fixation▪ One-tray instrumentation system ▪ One-tray instrumentation ideal for ASC 66
2 Positioned to Win in High Growth ASC Segment… ASC: A VERY HIGH GROWTH SEGMENT DRIVERS OF ASC EXPANSION 1 TJA Procedures in ASC (000’s) ▪ Medicare approved reimbursement in 2018-19 ▪ 40% less expensive for Medicare in ASC 1,108 ▪ Faster recovery + lower infection/complication rates 333 1,057 ▪ Physician has ownership in entire patient journey 1,158 29% CAGR 345 1,330 300 520 ▪ Patient selection critical based on 23hr stay 107 2020 2025 2030 Inpatient HOPD ASC DJO ADVANTAGED POSITION 1 2 3 4 5 DEEP BRACING SURGICAL PORTFOLIO NEXT GENERATION TRADITIONAL “BIG 4” BROAD-BASED MARKET PENETRATION OPTIMIZED FOR ASC CAS SOLUTIONS MARKET ADVANTAGES COLLABORATION WITH IN ASC SEGMENT “MIX” OF PATIENTS TAILORED FOR ASC NULLIFIED IN ASC LEADING ASC SURGEONS 67 1 Source: based on Medtech analysis2 Positioned to Win in High Growth ASC Segment… ASC: A VERY HIGH GROWTH SEGMENT DRIVERS OF ASC EXPANSION 1 TJA Procedures in ASC (000’s) ▪ Medicare approved reimbursement in 2018-19 ▪ 40% less expensive for Medicare in ASC 1,108 ▪ Faster recovery + lower infection/complication rates 333 1,057 ▪ Physician has ownership in entire patient journey 1,158 29% CAGR 345 1,330 300 520 ▪ Patient selection critical based on 23hr stay 107 2020 2025 2030 Inpatient HOPD ASC DJO ADVANTAGED POSITION 1 2 3 4 5 DEEP BRACING SURGICAL PORTFOLIO NEXT GENERATION TRADITIONAL “BIG 4” BROAD-BASED MARKET PENETRATION OPTIMIZED FOR ASC CAS SOLUTIONS MARKET ADVANTAGES COLLABORATION WITH IN ASC SEGMENT “MIX” OF PATIENTS TAILORED FOR ASC NULLIFIED IN ASC LEADING ASC SURGEONS 67 1 Source: based on Medtech analysis
2 …As the Leader Across the Episode of Care LEADING THE WAY ▪ Only company to support entire continuum of care ▪ Freshest, most differentiated technology portfolio ▪ Clear leadership in digital workflow solutions for ASC ASC360 Delivers with Products & Solutions Throughout the Patient Journey 682 …As the Leader Across the Episode of Care LEADING THE WAY ▪ Only company to support entire continuum of care ▪ Freshest, most differentiated technology portfolio ▪ Clear leadership in digital workflow solutions for ASC ASC360 Delivers with Products & Solutions Throughout the Patient Journey 68
Leading in Digital Healthcare with Nextgen CAS (Computer Assisted 3 Surgery) Technologies Today 2021 Launches 2022 & Beyond 1 Leading Pre-Op Planning & PSI Best-in-class Pre-Op Planning & Expand range of innovative ▪▪▪ 1 solution for Shoulder PSI for Total Ankle Augmented Reality (A/R) Navigation platform Match Point™ System used in Innovative Augmented Reality ▪▪ ~30% of MedTechCo shoulder (A/R) Navigation platform for Add small footprint robotics ▪ cases Knee & Hip platform Arvis™ AR End State: Full CAS Solution Equipping surgeons with Aim, Set, Matched™ across all anatomies, advantaged necessary tools to improve 2 in the ASC environment clinical outcomes 1 Patient Specific Instrumentation, 69 2 Ambulatory Surgery CenterLeading in Digital Healthcare with Nextgen CAS (Computer Assisted 3 Surgery) Technologies Today 2021 Launches 2022 & Beyond 1 Leading Pre-Op Planning & PSI Best-in-class Pre-Op Planning & Expand range of innovative ▪▪▪ 1 solution for Shoulder PSI for Total Ankle Augmented Reality (A/R) Navigation platform Match Point™ System used in Innovative Augmented Reality ▪▪ ~30% of MedTechCo shoulder (A/R) Navigation platform for Add small footprint robotics ▪ cases Knee & Hip platform Arvis™ AR End State: Full CAS Solution Equipping surgeons with Aim, Set, Matched™ across all anatomies, advantaged necessary tools to improve 2 in the ASC environment clinical outcomes 1 Patient Specific Instrumentation, 69 2 Ambulatory Surgery Center
® 3 Leading in Digital Healthcare with MotionMD SAAS WORKFLOW AUTOMATION SOFTWARE SOLUTION CLINIC LOCATION GROWTH PRODUCT REVENUE GROWTH (CAGR) (CAGR) +18% +74% 2,350 $65M 445 $40M 2017 2017 2020 2020 WINNING WITH WORKFLOW SOLUTIONS Secure. Paperless. Integrated ▪ 40% share in US clinics / used by over 30K medical professionals ▪ Key driver in large Hospital owned conversions $8M 2020 24% 8% 40% ▪ MotionMD® revenue delivers 600 bps higher gross margin Reduction in Improvement Reduction in inventory in collections Billing lead ▪ Customer Retention Rate of 99% time ▪ Share of wallet Direct 70% / OfficeCare® 96% 70® 3 Leading in Digital Healthcare with MotionMD SAAS WORKFLOW AUTOMATION SOFTWARE SOLUTION CLINIC LOCATION GROWTH PRODUCT REVENUE GROWTH (CAGR) (CAGR) +18% +74% 2,350 $65M 445 $40M 2017 2017 2020 2020 WINNING WITH WORKFLOW SOLUTIONS Secure. Paperless. Integrated ▪ 40% share in US clinics / used by over 30K medical professionals ▪ Key driver in large Hospital owned conversions $8M 2020 24% 8% 40% ▪ MotionMD® revenue delivers 600 bps higher gross margin Reduction in Improvement Reduction in inventory in collections Billing lead ▪ Customer Retention Rate of 99% time ▪ Share of wallet Direct 70% / OfficeCare® 96% 70
Leading in Digital Healthcare and Moving Beyond the Brace with 3 ® MotioniQ ULTIMATE WEARABLE TECHNOLOGY TRANSITIONING TO SMART ▪ SmartBrace™ transforming “in-protocol” brace into wearable tech: ‒ 20%+ ASP expansion expected ▪ Opens pathway to large existing markets ‒ Remote patient monitoring ‒ Outpatient/Home-based Physical Therapy ▪ Creates new markets that don’t exist today ‒ AI / Big Data enables patients to manage progressive conditions MEDTECHCO COMPETITIVE ADVANTAGE ▪ Leading BAS positions in Knee, Walker Boots, Spine, Upper extremity, etc. ‒ X4 in market today ‒ X-ROM iQ and SRB iQ launching Q3 21 MotioniQ® allows doctors and patients to virtually walk side by side on the road from diagnosis through rehabilitation with education, ‒ VOC on additional smart products ongoing with leading centers exercises, progress monitoring, and connected solutions. ‒ Future products in spine and shoulder ▪ Able to leverage installed base of MotionMD® in ~40%+ of clinics 71Leading in Digital Healthcare and Moving Beyond the Brace with 3 ® MotioniQ ULTIMATE WEARABLE TECHNOLOGY TRANSITIONING TO SMART ▪ SmartBrace™ transforming “in-protocol” brace into wearable tech: ‒ 20%+ ASP expansion expected ▪ Opens pathway to large existing markets ‒ Remote patient monitoring ‒ Outpatient/Home-based Physical Therapy ▪ Creates new markets that don’t exist today ‒ AI / Big Data enables patients to manage progressive conditions MEDTECHCO COMPETITIVE ADVANTAGE ▪ Leading BAS positions in Knee, Walker Boots, Spine, Upper extremity, etc. ‒ X4 in market today ‒ X-ROM iQ and SRB iQ launching Q3 21 MotioniQ® allows doctors and patients to virtually walk side by side on the road from diagnosis through rehabilitation with education, ‒ VOC on additional smart products ongoing with leading centers exercises, progress monitoring, and connected solutions. ‒ Future products in spine and shoulder ▪ Able to leverage installed base of MotionMD® in ~40%+ of clinics 71
3 Defining the Future of Connected Medicine X4 SMART BRACE SMART POST-OP BRACES Connected TKA Solution ACL Connected Solutions ▪ Expanding SmartBrace into Sports Medicine ▪ Outpatient/ASC driving postop TJA out of inpatient therapy ▪ Drives higher ASPs into traditional bracing protocols ▪ Large segment with 1M procedures annually ▪ Transforming rehab with personalized, in- ▪ The first wearable technology in bracing – home protocols tracking steps, ROM, and gait ▪ Focused on return to performance vs return ▪ Enabled tele-medicine protocol connecting patient to mobility to HCP across episode of care 723 Defining the Future of Connected Medicine X4 SMART BRACE SMART POST-OP BRACES Connected TKA Solution ACL Connected Solutions ▪ Expanding SmartBrace into Sports Medicine ▪ Outpatient/ASC driving postop TJA out of inpatient therapy ▪ Drives higher ASPs into traditional bracing protocols ▪ Large segment with 1M procedures annually ▪ Transforming rehab with personalized, in- ▪ The first wearable technology in bracing – home protocols tracking steps, ROM, and gait ▪ Focused on return to performance vs return ▪ Enabled tele-medicine protocol connecting patient to mobility to HCP across episode of care 72
4 Acquired Strong Position in High Growth Foot/Ankle Recon Market 1 US MARKET SIZE , $ (~$1.1B IN 2019), ~7% CAGR Product Coverage ® Star Trilliant Ankle Ankle Hindfoot Midfoot Forefoot (Including Bunion, Hallux Recon Fusion Rigidus, Hammertoe) F&A STRATEGY ® ® ▪ Capitalize on 90% of non-common surgeon base of Star and Trilliant ® ▪ Expand and freshen Star to 100% coverage in Recon with PSI and revision portfolio ® ▪ Accelerate Trilliant expansion in fusion: Leverage strength in forefoot to mid and hindfoot ▪ Expand into attractive verticals via NPI and inorganic opportunities ▪ Deploy “Surgical” playbook of innovation cadence, KOL leadership, medical education and contracting breadth ▪ Capitalize on P&R depth in Foot & Ankle Positioned to expand across segments including attractive verticals 73 1 Source: based on internal Medtech analysis4 Acquired Strong Position in High Growth Foot/Ankle Recon Market 1 US MARKET SIZE , $ (~$1.1B IN 2019), ~7% CAGR Product Coverage ® Star Trilliant Ankle Ankle Hindfoot Midfoot Forefoot (Including Bunion, Hallux Recon Fusion Rigidus, Hammertoe) F&A STRATEGY ® ® ▪ Capitalize on 90% of non-common surgeon base of Star and Trilliant ® ▪ Expand and freshen Star to 100% coverage in Recon with PSI and revision portfolio ® ▪ Accelerate Trilliant expansion in fusion: Leverage strength in forefoot to mid and hindfoot ▪ Expand into attractive verticals via NPI and inorganic opportunities ▪ Deploy “Surgical” playbook of innovation cadence, KOL leadership, medical education and contracting breadth ▪ Capitalize on P&R depth in Foot & Ankle Positioned to expand across segments including attractive verticals 73 1 Source: based on internal Medtech analysis
5 Recent Portfolio Investments Reshaping our Business Entering AR Surgical ASC High growth Projected Foot & Ankle Platform Solutions Modalities Portfolio Impact ▪ >$1B Market▪ Next Gen TJA ▪ Double digit ▪ HSD growth system procedural category ▪ HSD growth volume growth >$100M category▪ Footprint and ▪ Synergy 2023 Sales cost positioned ▪ Provides opportunities ▪ Fragmented for ASC Surgical competition assistance▪ Expanded applications DD+ CAGR Arvis™ AR ADAPTABLE® Litecure™ Laser STAR / Trilliant 75%+ Gross Margins 745 Recent Portfolio Investments Reshaping our Business Entering AR Surgical ASC High growth Projected Foot & Ankle Platform Solutions Modalities Portfolio Impact ▪ >$1B Market▪ Next Gen TJA ▪ Double digit ▪ HSD growth system procedural category ▪ HSD growth volume growth >$100M category▪ Footprint and ▪ Synergy 2023 Sales cost positioned ▪ Provides opportunities ▪ Fragmented for ASC Surgical competition assistance▪ Expanded applications DD+ CAGR Arvis™ AR ADAPTABLE® Litecure™ Laser STAR / Trilliant 75%+ Gross Margins 74
5 Expand Through M&A Strengthen & Extend Current Business Within Orthopedic Market Logical MedTech Adjacencies Recon Technology Geographical application in expansion other markets High growth Sub- Foot & Ankle segments expansion Minimally Invasive High growth Surgery High Margin P&R Orthopedic Enabling Devices MEDTECHCO Clinic-based Digital adjacencies Solutions & Technologies AQUISITION CRITERIA ▪ Fuels growth ▪ Accelerates strategy▪ Creates scale ▪ Mid 60’s or better gross margin ▪ Expands market reach 755 Expand Through M&A Strengthen & Extend Current Business Within Orthopedic Market Logical MedTech Adjacencies Recon Technology Geographical application in expansion other markets High growth Sub- Foot & Ankle segments expansion Minimally Invasive High growth Surgery High Margin P&R Orthopedic Enabling Devices MEDTECHCO Clinic-based Digital adjacencies Solutions & Technologies AQUISITION CRITERIA ▪ Fuels growth ▪ Accelerates strategy▪ Creates scale ▪ Mid 60’s or better gross margin ▪ Expands market reach 75
Realizing our Vision – Specialty Med Tech Innovator LONG-TERM MEDTECHCO SALES STRATEGIC GOALS HSD P&R Core Growth Recon Extend & expand New high growth segments ~$1.7-2B Mid-60s Aggressively Gross Margin grow and Scale recon expand recon $1.4B >25% Improve and 2 Extend P&R aEBITDA Margin shape P&R leadership 1 Today 2023 Future 1 2021 estimated sales 76 2 Segment-level marginRealizing our Vision – Specialty Med Tech Innovator LONG-TERM MEDTECHCO SALES STRATEGIC GOALS HSD P&R Core Growth Recon Extend & expand New high growth segments ~$1.7-2B Mid-60s Aggressively Gross Margin grow and Scale recon expand recon $1.4B >25% Improve and 2 Extend P&R aEBITDA Margin shape P&R leadership 1 Today 2023 Future 1 2021 estimated sales 76 2 Segment-level margin
Restored to MSD+ Core Growth, Acceleration Ahead SALES ($B) PROGRESS 8% 5% 4% 2% Supply chain investment and CBS ▪ improvements restored P&R growth in Q1 Q2 Q3 Q4 2H 2019 $1.3-$1.4 Strong Reconstructive innovation and ▪ increasing P&R vitality $1.25 $1.20 $1.19 $1.16 $1.12 Recently completed 3 fast-growing ▪ acquisitions Built strong team and investing in ▪ commercial capabilities Outgrew market in 2020 and expect ▪ 1 1 2016 2017 2018 2019 2020 2021E Future strong recovery in 2021 and beyond COVID Core MSD+ 14-16% Growth 4% 3% 2% 4% (11%) to HSD Core vs PY 21-24% Acq’d by Colfax Reported 77 1 See appendix for non-GAAP reconciliations, 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019Restored to MSD+ Core Growth, Acceleration Ahead SALES ($B) PROGRESS 8% 5% 4% 2% Supply chain investment and CBS ▪ improvements restored P&R growth in Q1 Q2 Q3 Q4 2H 2019 $1.3-$1.4 Strong Reconstructive innovation and ▪ increasing P&R vitality $1.25 $1.20 $1.19 $1.16 $1.12 Recently completed 3 fast-growing ▪ acquisitions Built strong team and investing in ▪ commercial capabilities Outgrew market in 2020 and expect ▪ 1 1 2016 2017 2018 2019 2020 2021E Future strong recovery in 2021 and beyond COVID Core MSD+ 14-16% Growth 4% 3% 2% 4% (11%) to HSD Core vs PY 21-24% Acq’d by Colfax Reported 77 1 See appendix for non-GAAP reconciliations, 2019 shown pro forma to include periods prior to DJO acquisition on February 22, 2019
Clear Path to Margin Expansion… 1 MEDTECH aEBITDA MARGINS (%) MARGIN EXPANSION LEVERS Improvements 2016 19 • Recon mix ▪ Portfolio Shift to Recon • Structural reductions ▪ Product Mix in P&R 1 2019 22 ▪ CBS driving productivity Investments & Acquisitions offset 2020 18 COVID productivity ▪ Operating leverage 2021E 20-21 2 ▪ Streamline SG&A and Expansion Plan scale acquisitions • Gross Margin improvement 1 Future 25+ • P&L Leverage 2 78 1 Segment-level margin, see appendix for non-GAAP reconciliation Clear Path to Margin Expansion… 1 MEDTECH aEBITDA MARGINS (%) MARGIN EXPANSION LEVERS Improvements 2016 19 • Recon mix ▪ Portfolio Shift to Recon • Structural reductions ▪ Product Mix in P&R 1 2019 22 ▪ CBS driving productivity Investments & Acquisitions offset 2020 18 COVID productivity ▪ Operating leverage 2021E 20-21 2 ▪ Streamline SG&A and Expansion Plan scale acquisitions • Gross Margin improvement 1 Future 25+ • P&L Leverage 2 78 1 Segment-level margin, see appendix for non-GAAP reconciliation
…with Accelerated FCF Conversion 1 SEGMENT OPERATING FREE CASH FLOW CONVERSION (%) HIGHLIGHTS CBS-driven process ▪ 90+% improvements drove strong Q4 ~80% 2020 performance 2021 includes working capital ▪ 55% investment to support COVID- recovery high growth rates ~25% Investing in Reconstructive growth ▪ Clear line of sight to 90%+ ▪ conversion while supporting MSD+ 2019 2020 2021E Future growth Cash Flow Expected to Scale with Business Growth 79 1 FCF Conversion is on a segment basis, unlevered. Calculated as FCF excluding tax payments divided by aEBITA…with Accelerated FCF Conversion 1 SEGMENT OPERATING FREE CASH FLOW CONVERSION (%) HIGHLIGHTS CBS-driven process ▪ 90+% improvements drove strong Q4 ~80% 2020 performance 2021 includes working capital ▪ 55% investment to support COVID- recovery high growth rates ~25% Investing in Reconstructive growth ▪ Clear line of sight to 90%+ ▪ conversion while supporting MSD+ 2019 2020 2021E Future growth Cash Flow Expected to Scale with Business Growth 79 1 FCF Conversion is on a segment basis, unlevered. Calculated as FCF excluding tax payments divided by aEBITA
Summary Specialty MedTech innovator uniquely positioned for significant value creation ▪ Foundation in attractive Orthopedic market with favorable long term mega-trends ▪ Strong team leading evolving portfolio and accelerating growth ▪ Clear strategy with exciting pipeline of new products, digital expansions and ASC ▪ solutions Significant acquisition opportunities in attractive spaces with appealing financial ▪ profiles CBS integrated to deliver compounding value creation ▪ 80Summary Specialty MedTech innovator uniquely positioned for significant value creation ▪ Foundation in attractive Orthopedic market with favorable long term mega-trends ▪ Strong team leading evolving portfolio and accelerating growth ▪ Clear strategy with exciting pipeline of new products, digital expansions and ASC ▪ solutions Significant acquisition opportunities in attractive spaces with appealing financial ▪ profiles CBS integrated to deliver compounding value creation ▪ 80
Q&AQ&A
Financial Update and Wrap-Up Chris Hix, EVP & CFOFinancial Update and Wrap-Up Chris Hix, EVP & CFO
Colfax Sustainable Model for Compounding Value Creation Talent Above-Market Sales Growth Innovation 1 2021E Margin Expansion CBS / Continuous Improvement Healthy Free Cash Flow Acquisitions / 1 Portfolio Shaping 2021E Each Business Now has Our Core Capabilities to Drive Superior Performance 83 1 2021 estimated sales Colfax Sustainable Model for Compounding Value Creation Talent Above-Market Sales Growth Innovation 1 2021E Margin Expansion CBS / Continuous Improvement Healthy Free Cash Flow Acquisitions / 1 Portfolio Shaping 2021E Each Business Now has Our Core Capabilities to Drive Superior Performance 83 1 2021 estimated sales
2021 Financial Outlook As originally communicated February 18, 2021 MedTech ESAB▪ Expecting robust growth in 2021 in sales, earnings, Sales growth and cash flow Organic 14%-16% 9%-12% ▪ Strong operating leverage, net of investments: MT Reported 21%-24% 11%-14% 50%+, FT 30%+ ▪ $25-30M of restructuring benefits aEBITA margin▪ ~$60M of 2020 COVID-driven temp cost actions coming back into businesses in 2021 Core + >400 bps + >50 bps ▪ Depreciation of ~$65M in MedTechCo and ~$40M in Acquisition Margins MSD ESAB Colfax ▪ Total corporate costs of ~$65M, excluding costs relating to the separation aEPS $2.00 - $2.15 >40% Growth FCF > $250M ▪ Q1 Guidance: aEPS of $0.35 - $0.40 Strong Growth Projected Across Both Businesses in 2021 842021 Financial Outlook As originally communicated February 18, 2021 MedTech ESAB▪ Expecting robust growth in 2021 in sales, earnings, Sales growth and cash flow Organic 14%-16% 9%-12% ▪ Strong operating leverage, net of investments: MT Reported 21%-24% 11%-14% 50%+, FT 30%+ ▪ $25-30M of restructuring benefits aEBITA margin▪ ~$60M of 2020 COVID-driven temp cost actions coming back into businesses in 2021 Core + >400 bps + >50 bps ▪ Depreciation of ~$65M in MedTechCo and ~$40M in Acquisition Margins MSD ESAB Colfax ▪ Total corporate costs of ~$65M, excluding costs relating to the separation aEPS $2.00 - $2.15 >40% Growth FCF > $250M ▪ Q1 Guidance: aEPS of $0.35 - $0.40 Strong Growth Projected Across Both Businesses in 2021 84
Strong Paths to Margin Expansion ▪ Strong decremental performance in 1 Colfax aEBITDA Margins 2020: ~14 points less than natural operating leverage MedTechCo 17.1% 16.5 - 17.0% ▪ Return to our continuous improvement Strategic Goal of path in 2021 2 > 25% 15.2% ▪ Both businesses expected to have future benefit from operating leverage, ESAB productivity, innovation, acquisitions Strategic Goal of 2 > 20% ▪ Expect additional corporate costs of ~$15M post-separation; total costs split- weighted more to MedTechCo 2019 2020 2021E Future Excluding Corporate Costs Clear Lines of Sight to Margin Expansion 1 See appendix for non-GAAP reconciliations. 85 2 Segment-level aEBITDA margins.Strong Paths to Margin Expansion ▪ Strong decremental performance in 1 Colfax aEBITDA Margins 2020: ~14 points less than natural operating leverage MedTechCo 17.1% 16.5 - 17.0% ▪ Return to our continuous improvement Strategic Goal of path in 2021 2 > 25% 15.2% ▪ Both businesses expected to have future benefit from operating leverage, ESAB productivity, innovation, acquisitions Strategic Goal of 2 > 20% ▪ Expect additional corporate costs of ~$15M post-separation; total costs split- weighted more to MedTechCo 2019 2020 2021E Future Excluding Corporate Costs Clear Lines of Sight to Margin Expansion 1 See appendix for non-GAAP reconciliations. 85 2 Segment-level aEBITDA margins.
Improved Cash Flow Capabilities ▪ Stabilized MedTech segment in 2019 ▪ Significant process improvements across Colfax Free Cash Flow (FCF) Conversion Colfax in 2020 • MedTechCo 90%+ 1 ▪ Expecting > $250M of FCF in 2021; Conversion • Capital Allocation expect to deploy primarily for de- Focused on Growth leveraging and MedTech acquisitions ▪ Current performance trajectory points 97% ~90% • ESAB 100%+ to year-end leverage of low 3x before 1 57% Conversion additional acquisition investments • Balanced Capital ▪ Expect to establish prudent capital Allocation structures for each business that are 2 consistent with respective capital 2019 2020 2021E Future allocation priorities and strategies Clear Path for Healthy FCF Generation in Both Businesses 1 Segment-level operating free cash flow conversion 86 2 Excludes transaction costs and one-time DJO working capital investmentsImproved Cash Flow Capabilities ▪ Stabilized MedTech segment in 2019 ▪ Significant process improvements across Colfax Free Cash Flow (FCF) Conversion Colfax in 2020 • MedTechCo 90%+ 1 ▪ Expecting > $250M of FCF in 2021; Conversion • Capital Allocation expect to deploy primarily for de- Focused on Growth leveraging and MedTech acquisitions ▪ Current performance trajectory points 97% ~90% • ESAB 100%+ to year-end leverage of low 3x before 1 57% Conversion additional acquisition investments • Balanced Capital ▪ Expect to establish prudent capital Allocation structures for each business that are 2 consistent with respective capital 2019 2020 2021E Future allocation priorities and strategies Clear Path for Healthy FCF Generation in Both Businesses 1 Segment-level operating free cash flow conversion 86 2 Excludes transaction costs and one-time DJO working capital investments
Next Steps Continue to execute our profitable growth strategy Determine form of separation, prepare SEC filings Create separate corporate capabilities Establish capital structures to match allocation priorities, strategies Take other steps to satisfy conditions for targeted Q1 ‘22 separation 87Next Steps Continue to execute our profitable growth strategy Determine form of separation, prepare SEC filings Create separate corporate capabilities Establish capital structures to match allocation priorities, strategies Take other steps to satisfy conditions for targeted Q1 ‘22 separation 87
Investor Day 2021 Wrap-Up ✓ Taking the next logical step, given transformation of both businesses and opportunities ahead ✓ Strong momentum in both businesses ✓ Exciting visions for ESAB and MedTechCo ✓ Separation should enable both businesses to achieve visions and unlock value Focus on Superior Long-term Shareholder Value Creation 88Investor Day 2021 Wrap-Up ✓ Taking the next logical step, given transformation of both businesses and opportunities ahead ✓ Strong momentum in both businesses ✓ Exciting visions for ESAB and MedTechCo ✓ Separation should enable both businesses to achieve visions and unlock value Focus on Superior Long-term Shareholder Value Creation 88
Q&AQ&A
Appendix 90Appendix 90
Non-GAAP Reconciliation _____________________ Note: Dollars in millions. 91Non-GAAP Reconciliation _____________________ Note: Dollars in millions. 91
Non-GAAP Reconciliation __________ (1) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 92Non-GAAP Reconciliation __________ (1) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 92
Non-GAAP Reconciliation __________ (1) The Net sales and Adjusted EBITDA figures for the two months ended February 22, 2019 are based on or derived from Management’s internal reports. The Colfax 2020 Form 10-K only includes prior year Medical Technology segment results subsequent to February 22, 2019, the date of the DJO acquisition. (2) Restructuring and other related charges includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 93Non-GAAP Reconciliation __________ (1) The Net sales and Adjusted EBITDA figures for the two months ended February 22, 2019 are based on or derived from Management’s internal reports. The Colfax 2020 Form 10-K only includes prior year Medical Technology segment results subsequent to February 22, 2019, the date of the DJO acquisition. (2) Restructuring and other related charges includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 93
Non-GAAP Reconciliation __________ (1) Medical Technology prior year Net sales and sales components are based on or derived from Management’s internal reports. On the Company’s 2020 and 2019 form 10-K reports, Medical Technology prior year Net sales include only sales subsequent to February 22, 2019, the date of the DJO acquisition, and sales prior to February 22, 2020 are included in the Acquisitions line item of the change in sales reconciliation. (2) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume. (3) Represents the incremental sales from acquisitions. (4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 94Non-GAAP Reconciliation __________ (1) Medical Technology prior year Net sales and sales components are based on or derived from Management’s internal reports. On the Company’s 2020 and 2019 form 10-K reports, Medical Technology prior year Net sales include only sales subsequent to February 22, 2019, the date of the DJO acquisition, and sales prior to February 22, 2020 are included in the Acquisitions line item of the change in sales reconciliation. (2) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume. (3) Represents the incremental sales from acquisitions. (4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 94
Non-GAAP Reconciliation __________ (1) Restructuring and other related charges includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (3) Includes costs incurred for the acquisition of DJO. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 95Non-GAAP Reconciliation __________ (1) Restructuring and other related charges includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (3) Includes costs incurred for the acquisition of DJO. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 95
Non-GAAP Reconciliation __________ (1) 2019 Free cash flow includes cash outflows for strategic transaction costs and DJO incremental first year working capital investments of approximately $110 and $40, respectively. (2) Refer to the Adjusted net income non-GAAP reconciliation within this appendix for the calculation of Adjusted net income for the years ended December 31, 2020 and 2019. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 96Non-GAAP Reconciliation __________ (1) 2019 Free cash flow includes cash outflows for strategic transaction costs and DJO incremental first year working capital investments of approximately $110 and $40, respectively. (2) Refer to the Adjusted net income non-GAAP reconciliation within this appendix for the calculation of Adjusted net income for the years ended December 31, 2020 and 2019. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 96
Non-GAAP Reconciliation __________ (1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $3.1 and $4.6 for the years ended December 31, 2020 and 2019, respectively. Net income from continuing operations attributable to Colfax Corporation for the year ended December 31, 2020 includes a $6.8 discrete tax benefit associated with the filing of timely elected changes to U.S. Federal tax returns to credit rather than to deduct foreign taxes. The discrete benefit has been excluded from the effective tax rates used to calculate adjusted net income. (2) Restructuring and other related charges - pretax includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. (5) Includes costs incurred for the acquisition of DJO. (6) The effective tax rates used to calculate Adjusted net income were 23.3% and 21.9% for the years ended December 31, 2020 and 2019, respectively. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 97Non-GAAP Reconciliation __________ (1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of $3.1 and $4.6 for the years ended December 31, 2020 and 2019, respectively. Net income from continuing operations attributable to Colfax Corporation for the year ended December 31, 2020 includes a $6.8 discrete tax benefit associated with the filing of timely elected changes to U.S. Federal tax returns to credit rather than to deduct foreign taxes. The discrete benefit has been excluded from the effective tax rates used to calculate adjusted net income. (2) Restructuring and other related charges - pretax includes $6.6 and $8.5 of expense classified as Cost of sales on the Company’s Consolidated Statements of Operations for the years ended December 31, 2020 and December 31, 2019, respectively. (3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. (4) Includes amortization of acquired intangibles and fair value charges on acquired inventory. (5) Includes costs incurred for the acquisition of DJO. (6) The effective tax rates used to calculate Adjusted net income were 23.3% and 21.9% for the years ended December 31, 2020 and 2019, respectively. _____________________ Note: Dollars in millions. Some periods may not foot due to rounding. 97